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 ABSTRACT 
 Campylobacter is the leading cause of foodborne illness worldwide and human illnesses 
are often associated with consumption of poultry or poultry products.  Many strategies have been 
tried to eliminate Campylobacter from poultry with limited success.  One of the strategies to 
reduce Campylobacter colonization in poultry is by use of probiotics.  We conducted 2 separate 
studies to evaluate the efficacy of probiotics against Campylobacter in broiler chickens.  For our 
first study, GRAS (Generally Regarded as Safe) bacteria were isolated from healthy chickens and 
tested their efficacy against Campylobacter in vitro.  Twenty six isolates with in vitro anti-
Campylobacter activity were selected and tested in broiler chickens.  Only 3 out of 26 isolates 
tested, demonstrated a 1-2 log reduction in Campylobacter colonization.  To further improve the 
in vivo efficacy of these 3 isolates, these isolates were given along with 3 different doses of a 
prebiotic (fructoligosaccharide/FOS or mannanoligosaccharide/MOS).  Of all the treatments 
tested, only one isolate when combined with 0.04% MOS showed a 3 log reduction in 
Campylobacter.  However, the isolates which reduced Campylobacter in vivo in our initial trials 
failed to reduce Campylobacter in subsequent trials.  One possible explanation for such 
inconsistencies could be due to destruction of probiotic isolates in the acidic environment of 
stomach.  Encapsulation of isolates may overcome this problem, but there is no assurance that 
these isolates will have efficiency in the lower intestine.  In the second study, a procedure to 
screen the in vivo efficacy of candidate isolates was developed by directly inoculating isolates in 
the lower intestinal tract via the cloaca.  For this study GRAS bacterial isolates with enhanced 
motility and in vitro anti-Campylobacter activity were selected and tested in vivo by dosing the 
isolates either orally or intra-cloacally.  When isolates were dosed orally, only one isolate showed 
a 1 log reduction in Campylobacter, but when these isolates were administered intra-cloacally, 
 five of these isolates produced a 1-3 log reduction in cecal Campylobacter counts.  These results 
support the strategy of evaluating the efficacy of potential probiotic isolates via cloacal 
inoculation prior to undergoing the effort of protecting isolates (e.g., encapsulation) for oral 
administration. 
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INTRODUCTION 
 Foodborne illnesses are a growing public health problem worldwide (WHO, 2011).  
Gastrointestinal symptoms are the most common clinical manifestation of foodborne illness, 
caused by a wide range of microorganisms including bacteria, viruses and parasites (WHO, 
2013b).  It has been estimated that diarrheal diseases alone are responsible for 1.7 - 2.5 million 
deaths globally every year and a significant proportion of these deaths are due to consumption of 
contaminated food and/or water (WHO, 2009).  It has been indicated that foodborne diseases are 
more common in developing and underdeveloped countries, and are often reported to be 
associated with poor sanitation and poor socio-economic conditions (WHO, 2012).  However, 
foodborne illnesses are no longer limited to developing countries.  Epidemiological evidence 
indicates that one in three persons in developed countries are affected by foodborne illnesses 
each year (WHO, 2013a).  In United States alone, foodborne diseases result in 47.8 million 
illnesses, 127,839 hospitalizations and 3,037 deaths every year (CDC, 2013a).  The economic 
loss due to foodborne illnesses in the US was estimated to be about $77.7 billion (Scharff, 2012).  
Epidemiological data indicate that Campylobacter is one of the leading causes of foodborne 
illness in the United States after Salmonella (CDC, 2013b).  Campylobacter has been reported to 
cause 400 million illnesses annually all over the world (Rollwagen, et al., 1993).  In the United 
States alone, Campylobacter illness was estimated to cost $1.7 billion annually (Batz, et al., 
2012; Hoffmann, et al., 2012).  In Canada, Campylobacter was found to be the causative agent 
for 59% of waterborne or foodborne enteritis cases being reported (Hannu et al., 2002).  
Campylobacter has been reported to be the most common cause of foodborne illness in the 
European Union (EU) also, and is estimated to cause around 9 million foodborne illnesses, 
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resulting in economic losses of €2.4 billion a year (EFSA, 2013a).  In Australia 5.4 million cases 
of foodborne illnesses were reported each year causing economic losses up to A$1.2 billion 
(AGDHA, 2006), and in New Zealand the losses were estimated to be around NZ$161.9 million, 
of which Campylobacter alone causes losses up to NZ$36 million (NZFSA, 2010). 
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Chapter 1 
LITERATURE REVIEW 
1.1 HISTORY 
 Campylobacter was first described by Theodor Escherich in 1886.  Escherich (1886) 
observed spiral shaped non-culturable bacteria from the colon of children who died of cholera 
infantum.  In 1906, two British veterinarians, McFadyean and Stockman isolated spiral shaped 
organisms from aborting ewes during their investigation of epizootic abortions in animals in the 
United Kingdom (Véron and Chatelain, 1973).  Later Smith (1919) isolated similar organisms 
from aborted bovine fetuses.  Smith along with Taylor (1919) speculated the organisms reported 
by McFadyean’s group and Smith to be the same and proposed the name Vibrio fetus for the 
microaerophilic organism responsible for abortions in cattle and sheep.  Jones and colleagues 
(1931) demonstrated curved vibrio-like bacteria from the jejunum of calves with winter 
dysentery and proposed the name Vibrio jejuni.  A few years later, Doyle (1944) isolated similar 
organisms from the intestine of swine with dysentery and named the organism Vibrio coli.  King 
first studied the strains of Vibrio causing diarrhea in humans and reported an unusually high 
optimal growth temperature requirement of some of the strains (King, 1957, 1962).  She referred 
to these strains as related Vibrios, which were later renamed as C. jejuni and C. coli (Véron and 
Chatelain, 1973).  Dekeyser and his colleagues successfully isolated Campylobacter from stool 
samples (Dekeyser, et al., 1972).  Sebald and Véron separated Campylobacters from Vibrio and 
proposed the new genus Campylobacter with Campylobacter fetus as the type species (Sebald 
and Véron, 1963).  Véron and Chatelain studied the previously reported microaerophilic Vibrios 
and reclassified V. fetus, V. coli, V. jejuni, V. sputorum sub spssputorum and V. sputorum sub sps 
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bubulus under the genus Campylobacter (Véron and Chatelain, 1973).  Prior to 1977, many 
scientists attempted to isolate Campylobacter using filteration techniques, but the development 
of selective media for Campylobacter (Skirrow, 1977) marked the beginning of the “era of 
Campylobacter research”. 
1.2 GENERAL CHARACTERISTICS  
1.2.1 Genus Campylobacter 
 The word Campylobacter is derived from a Greek word “kampulos” meaning curved and 
“bacter” meaning rod (Sebald and Véron, 1963).  The genus Campylobacter was classified under 
the family Campylobacteraceae and other members of the family include Arcobacter, 
Sulfurospirillum and Bacteroides ureolyticus (Debruyne, et al., 2008).  Currently there are 17 
recognized species under the genus Campylobacter and C. jejuni has been recognized as the 
predominant species responsible for majority of human enterocolitis infection (Butzler, et al., 
1973; Skirrow, 1977; Phillips, 1995; Debruyne, et al., 2008).  Approximately 5-10% of human 
infections may be caused by C. coli and rarely other species such as C. lari and C. upsaliensis 
can cause similar disease in some people (EFSA, 2013b). 
1.2.2 Morphological and growth characteristics of the genus Campylobacter 
 Members of the genus Campylobacter are Gram negative curved rods measuring 0.5-5µm 
long and 0.2-0.8µm wide (Smibert, 1978; Debruyne, et al., 2008).  The organisms are motile by 
means of a single polar flagellum at one or both ends (fig 1, Pead, 1979) and a show a 
characteristic corkscrew motility (Smibert, 1978).  Some exceptions have been reported, such as 
multiple flagella in C. showae and no flagella in species like C. gracilis (Percival, et al., 2004).  
 6 
 
Optimal growth was observed at 42⁰C under microaerophilic conditions, with an atmosphere 
containing 5% oxygen, 10% carbon dioxide, 85% nitrogen (King, 1957, 1962).  Campylobacters 
are known for their fastidious growth requirements and are believed to be sensitive to 
environmental stressors, including changes in pH, temperature and exposure to high oxygen 
concentration (Butzler and Oosterom, 1991; Park, 2002).  Contrary to the fastidious nature of the 
organism in the laboratory, Campylobacters can survive in water, as well as a wide range of food 
stuffs including meat, milk and other dairy products (Ziprin, 2004).  Some researchers have 
proposed that Campylobacter can resist environmental stressors and survive as a viable but non-
culturable form (VBNC, Cappelier, et al., 1999; Höller, et al., 1998; Rollins and Colwell, 1986; 
Tholozan, et al., 1999).  Rollins and Colwell (1986) first described the ability of Campylobacter 
to transform into a coccoid viable, but non-culturable state when exposed to environmental 
stress, such as fluctuations in temperature, pH, high oxygen concentration and starvation.  
However contradictory opinions were expressed about the ability of VBNC forms to become 
metabolically active and produce disease on exposure to favorable conditions (Cappelier, et al., 
1999; Park, 2002; Thomas, et al., 2002; Ziprin, et al., 2003; Ziprin and Harvey, 2004; Baffone, et 
al., 2006). 
1.3 CAMPYLOBACTER INFECTIONS IN HUMANS 
1.3.1 Incidence and epidemiology of Campylobacter 
 During the 1970’s Campylobacter emerged as a frequent cause of diarrheal illness in 
Europe and North America (Skirrow, 1982).  Campylobacter infections are the most frequently 
occurring foodborne gastroenteritis in the world (WHO, 2011).  It has been estimated that 
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Campylobacter infections are 2-7 times more frequent than Salmonella or Shigella infections 
(Allos, 2001).  It is often underreported even in developed countries like the United States.  A 
recent report shows that only one case out of every 38 C. jejuni infections has been reported 
(CDC, 2013b).  As per the CDC estimates, approximately 14.3 cases are reported per 100,000 
persons annually in the United States (CDC, 2013b).  Reported incidences are much higher 
during warmer months, especially during summer and fall (Allos, 2001).  Based on 
epidemiological data, the average incidence of Campylobacter in the European Union is 
estimated to be 50.28/100,000 population (EFSA, 2013b).  Surveillance data representing the 
incidence of campylobacteriosis per 100,000 persons from various countries has been shown in 
Table 1.  The number of cases reported from developing countries are often the number of 
laboratory confirmed cases (Coker, et al., 2002).  The true incidence in such countries could be 
many fold more than what is being reported (Coker, et al., 2002).  A very high incidence of 
40,000-60,000 cases per 100,000 population has been reported in children below 5 years in 
developing countries (Olson, et al., 2008).  Such a high prevalence of Campylobacter in 
developing countries pose increased risk to people travelling to such countries (Skirrow, 1990). 
1.3.2 Sources of infection 
 King first reported the possible role of handling and consumption of poultry as a major 
source of Campylobacter infections in humans (King, 1957, 1962).  This was further supported 
by many case control studies conducted in different parts of the world (Skirrow, 1982; Kapperud, 
et al., 2003; Stafford, et al., 2008; Danis, et al., 2009).  Other sources of infection for humans 
include unpasteurized milk (Blaser, et al., 1979b; Robinson, et al., 1979; Robinson and Jones, 
1981), water (Skirrow, 1982), fresh vegetables and fruits (Evans, et al., 2003; Danis, et al., 2009; 
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Verhoeff-Bakkenes, et al., 2011).  Contact with domestic animals and pets has also been 
demonstrated as a risk factor for human infections (Kapperud, et al., 2003; Stafford, et al., 2008; 
Danis, et al., 2009).  Poor hygiene and improper handling of food in domestic kitchens may cross 
contaminate fresh foods and thus may also act as sources for human infections (Danis, et al., 
2009).  Even though Campylobacter is prevalent in other food animals, retail pork and other red 
meats are less frequently contaminated with Campylobacter (Butzler and Oosterom, 1991; 
Evans, et al., 2003; Kapperud, et al., 2003; Zhao, et al., 2001; Danis, et al., 2009).  The high 
prevalence of Campylobacter in retail poultry can be attributed to high levels in ceca and the 
carcass handling in conventional processing plants (Butzler and Oosterom, 1991). 
1.3.3 Symptoms and sequaele 
 Campylobacter is one of the most common causes of foodborne enteritis in both 
developing and developed countries.  Many species of Campylobacter can cause illness in 
humans, but the majority of human infections (80-90%) were caused by C. jejuni (Butzler, et al., 
1973; Skirrow, 1977; Phillips, 1995; Debruyne, et al., 2008).  C. jejuni predominantly causes a 
self-limiting diarrheal illness in humans (Coker, et al., 2002).  A dose as low as 500 organisms 
can infect, colonize and produce disease symptoms in humans (Robinson, et al., 1979; Robinson 
and Jones, 1981).  Usually, the incubation period is between 2-11 days (Skirrow, 1977).  
Symptoms may range from mild watery diarrhea to severe mucoid bloody diarrhea (Wassenaar 
and Blaser, 1999).  Other symptoms associated with campylobacteriosis are abdominal pain, 
severe malaise, fever, headache, anorexia, nausea, vomiting and myalgia (Blaser, et al., 1979a).  
The affected patients may sometimes require supportive treatment, and in most cases affected 
patients recover without any antibiotic therapy (Peterson, 1994).  However antibiotic therapy is 
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recommended in cases of extra-intestinal infections and in immunocompromised people (Coker, 
et al., 2002).  It has been reported that Campylobacter may sometimes result in post infectious 
complications such as, Guillian Barré syndrome and Reactive arthritis (Peterson, 1994; Moore, et 
al., 2005). 
1.3.3.1 Guillain-Barré syndrome 
 Guillain, Barré and Strohl first described this neurological syndrome in two French soldiers 
exhibiting neurological signs (Guillain, et al., 1916).  Guillain-Barré syndrome (GBS) is an auto 
immune disorder, affecting the peripheral neurons, causing flaccid paralysis (Allos, 1997; 
Nachamkin, et al., 1998; Willison, 2005).  It has been described as a self-limiting disorder with a 
recovery period of several weeks to months (Nachamkin, et al, 1998).  However, 20% of the 
affected people may develop respiratory paralysis and may require mechanical ventilation 
(Nachamkin, et al, 1998; Kuwabara, 2004).  It has been estimated that the annual global 
incidence of Guillain-Barré syndrome is 1-4 cases/100,000 population (Hughes, et al., 1999; 
Kuwabara, 2004).  Case control studies have demonstrated that 1/1000 C. jejuni cases may 
develop post infectious complications like Guillain-Barré syndrome (Mishu, et al., 1993).  A 
preceding Campylobacter infection has been identified as one of the most frequent cause of 
Guillain-Barré syndrome (Kaldor and Speed, 1984; Rees, et al., 1995; Koga, et al., 1998).  Apart 
from Campylobacter, preceding infections with other agents such as Mycoplasma pneumonia, 
Cytomegalo virus, Epstein-barr virus, Varicella-zoster virus and vaccinations against swine 
influenza and rabies may predispose to Guillain-Barré syndrome (Nachamkin, 2002; Hughes and 
Cornblath, 2005). 
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 Several clinical forms of Guillain-Barré syndrome have been recognized such as Acute 
Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Acute Motor-Axonal Neuropathy 
(AMAN), Acute Motor-Sensory Axonal Neuropathy (AMSAN) and Miller Fisher syndrome 
(Hughes, et al., 1999).  C. jejuni infections are more commonly associated with the AMAN form 
of Guillain-Barré syndrome (Kuwabara, 2004; Komagamine and Yuki, 2006).  It has been 
proposed that the molecular mimicry between lipooligosaccharides of C. jejuni and host 
gangliosides may result in production of auto antibodies and thus, play a role in pathogenesis of 
Guillain-Barré syndrome (Yuki, et al., 2004; Komagamine and Yuki, 2006).  Researchers 
demonstrated that some strains of C. jejuni such as penner serotype HS: 19 are frequently 
associated with Guillain-Barré syndrome (Nachamkin, et al., 2002; Takahashi, et al., 2005).  
Also, the incidence was higher in males compared to females (Takahashi, et al., 2005).  
 C. jejuni may also cause Miller Fisher syndrome, a variant of Guillain-Barré syndrome, 
which is characterized by ataxia, loss of tendon reflexes (areflexia), ophthalmoplegia and 
presence of anti GQ1b antibodies in serum (Hughes, et al., 1999). 
1.3.3.2 Reactive arthritis 
 Up to 16% of Campylobacter infections may result in post infectious sequelae like 
Reactive arthritis in humans (Hannu, et al., 2002; Pope, et al., 2007).  Reactive arthritis, also 
referred as post infectious arthritis or Reiter’s syndrome, is characterized by inflammation of 
joints and tissues (Townes, 2010).  Preceding enteric or urogenital infections caused by 
pathogens such as Campylobacter, Salmonella, Shigella, Yersinia and Chlamydia may serve as 
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risk factors for Reactive arthritis (Townes, 2010).  Incidence was higher in adults than in 
children and also in the presence of Human leukocyte antigen, HLA-B27 (Pope, et al., 2007).  
1.3.4 Factors affecting Campylobacter infections in humans 
 Factors such as age, sex, seasonality and immune status may influence the incidence of 
campylobacteriosis in humans.  
i. Age:  Campylobacter infections are more common in children (below 5 years) and in 
young adults (Butzler, 2004; Friedman and Neimann, 2000).  The high incidence in young 
adults (15-44 years age), is commonly seen in developed countries, and could be due to 
food habits and frequent travel associated with this age group (Olson, et al., 2008).  
However, in developing countries, the incidence is much higher in children below 1 year 
and adults are relatively resistant to Campylobacter infections (Allos, 2001; Lee and 
Newell, 2006). 
ii. Sex:  For reasons unknown, males were 1.2-1.5 times more susceptible than females 
(Koehler, et al., 2006; Olson, et al., 2008). 
iii. Season:  Sporadic outbreaks of campylobacteriosis were common during warmer months, 
mainly during summer and early fall (Skirrow, 1987; Skirrow, 1990; Olson, et al., 2008; 
Senok and Botta, 2009; Jore, et al., 2010).  Seasonal influence on Campylobacter infections 
is more pronounced in temperate regions compared to developing countries in tropics 
(Allos, 2001; Nylen, et al., 2002). 
iv. Immune status:  Immunocompromised and HIV patients are 40-100 times more 
susceptible to Campylobacter infections (Wassenaar and Blaser, 1999; Butzler, 2004). 
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1.3.5 Mechanism of pathogenesis in humans 
 The mechanism by which Campylobacter causes disease symptoms may involve adhesion, 
colonization and invasion of intestinal epithelium.  As explained by Hugdahl and group (1988), 
flagellar motility and chemo attraction of Campylobacter towards mucin components (L-fucose 
and L-serine) may guide the organisms towards the favorable niche for colonization.  Adhesion 
of C. jejuni to the intestinal epithelium is mediated by factors such as flagellar adhesins, outer 
membrane proteins, fimbriae-like structures and lipooligosaccharide (Wassenaar and Blaser, 
1999).  Subsequent colonization and invasion are influenced by the virulence factors that are 
expressed by C. jejuni (van Vliet and Ketley, 2001).  The role of some of the virulence factors in 
the pathogenesis of C. jejuni has been briefly explained below:  
i. Flagella:  Research has shown that a functional flagellum is essential for chemotaxis, 
adhesion and invasion in humans (Wassenaar and Blaser, 1999).  Poor adhesion and 
invasion associated with aflagellar mutants further confirm the role of flagella in 
colonization and internalization (Yao, et al., 1993; Ziprin, et al., 1999). 
ii. Outer membrane protein, Cad F:  Cad F is one of the extensively studied Campylobacter 
adhesins (Krause-Gruszczynska, et al., 2007; Dasti, et al., 2010).  It has been proposed to 
bind to the host fibronectin (also called fibronectin binding protein) and facilitate 
colonization (Ziprin, et al., 2001). 
iii. Lipooligosaccharide (LOS):  LOS is an essential component of outer membrane of Gram 
negative cell wall.  It has been proposed to possess endotoxic activity and may also play a 
role in immune evasion (Wassenaar and Blaser, 1999; Young, et al., 2007).  Also, 
molecular mimicry between lipooligosaccharide structures of C. jejuni and neuronal 
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gangliosides of the host can lead to autoimmune disorders such as Guillain-Barré 
syndrome and Miller Fisher syndrome (Yuki, et al., 2004; Komagamine and Yuki, 2006). 
iv. Capsule:  The polysaccharide capsule of C. jejuni may also play a role in immune evasion, 
adhesion and invasion of epithelial cells (Young, et al., 2007). 
v. Lipoprotein A (JlpA):  Jlp A is a surface exposed lipoprotein which mediates adhesion to 
intestinal epithelial cells (Butzler and Oosterom, 1991). 
vi. Periplasmic or membrane associated protein (PEB 1):  PEB 1 is an adhesin located in 
the periplasm and is believed to play a role in adhesion to host cells (van Vliet and 
Ketley, 2001; Young, et al., 2007). 
vii. Cytolethal distending toxin (Cdt):  Almost all strains of C. jejuni and C. coli possess 
cdt genes and secrete cytolethal distending toxin, which may cause cytotoxicity (van 
Vliet and Ketley, 2001).  Cdt may also stimulate production of IL-8 in humans and 
thereby induce inflammation (Dasti et al., 2010).  Cdt may also play a role in immune 
evasion and in inducing immune tolerance (Dasti, et al., 2010). 
viii. Fimbriae like structures:  Some researchers indicate that C. jejuni may express 
fimbriae-like appendages when grown in the presence of bile salts, which may also play a 
role in adhesion (van Vliet and Ketley, 2001) 
 Apart from the virulence factors described above, certain other factors such as major outer 
membrane proteins, P95 and Campylobacter invasive antigens (Cia) may also play a role in 
Campylobacter colonization and disease production (Konkel, et al., 2001).  However, further 
research is needed to elucidate the exact mechanism by which Campylobacter produce disease in 
humans.  
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1.4 CAMPYLOBACTER IN POULTRY 
1.4.1 Prevalence of Campylobacter in poultry 
 Campylobacter occurs as a commensal in the GI tract of poultry and is reported to be 
prevalent in 70-100% of poultry flocks (Peterson, 1994).  A baseline study in Europe revealed 
that about 83% of poultry flocks and 98% of broiler carcasses were positive for Campylobacter 
(FSAI, 2011).  Many case control studies demonstrated that a very high percentage of retail 
chicken (more than 70%) sold in Europe and North America have been contaminated with 
Campylobacter (Stern and Line, 1992; Zhao, et al., 2001).  The high prevalence on retail poultry 
could be due to cross contamination during processing (Skirrow, 1990).  The percent prevalence 
of Campylobacter in poultry flocks and on retail poultry products is shown in Tables 2 and 3 
respectively.  Suzuki and Yamamoto (2009) reviewed the literature on Campylobacter 
contamination in retail poultry meats and poultry products from all over the world and concluded 
that at least 50% of retail poultry sold in most countries has been contaminated with 
Campylobacter.  Studies by Luangtongum and associates (2006) showed even higher risks 
associated with organic chicken and turkeys compared to conventionally raised birds. 
 Campylobacter has also been isolated from other birds such as pigeons, black birds, 
starlings and sparrows (Smibert, 1978; Skirrow, 1982).  Even though Campylobacter is 
considered nonpathogenic to poultry, earlier reports suggest that C. jejuni may be the causative 
agent of vibrionic hepatitis (Dekeyser, et al., 1972; Shane, 1992).  In case of Ostriches, C. jejuni 
and C. coli can cause Infectious Hepatitis, a disease similar to Vibrionic hepatitis and is 
characterized by brilliant green urates and severe necrotic hepatitis (Stephens, et al., 1998).  
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1.4.2 Colonization and transmission of Campylobacter in poultry 
 Campylobacters are reported to colonize the GI tract of poultry and domestic animals. It 
has been demonstrated that large numbers of Campylobacter (up to 109CFU/mL) colonize in the 
ceca, especially in the cecal crypts in avian species (Beery, et al., 1988).  Apart from the GI tract, 
they are also reported to colonize in some extra intestinal regions such as liver, spleen, gall 
bladder, thymus and reproductive tract (Newell and Fearnley, 2003; Cole, et al., 2004; Cox, et 
al., 2005). 
1.4.2.1 Horizontal transmission 
 Campylobacter naturally colonizes the ceca of healthy chickens by 2-4 weeks of age 
(Shane 1992; Jacobs-Reitsma, et al., 1995; van Gerwe, et al., 2009).  Initial protection from C. 
jejuni colonization, mainly during the first few weeks has been attributed to the presence of 
maternal antibodies (Shane 1992).  Subsequently poultry may acquire these organisms from 
contaminated fomites, untreated water, rodents, flies and free living birds (Altekruse, et al., 
1999; Corry and Atabay, 2001; Peterson, 1994).  Once a single bird has been colonized, they 
shed the organisms in feces, contaminate the litter, feed, water and within a few weeks, entire 
flock will be colonized (Stern, et al., 2001a; Newell and Fearnley, 2003).  Van Gerwe’s research 
group (2009) developed a mathematical model to quantify the rate of horizontal transmission in a 
broiler flock.  According to this model for every colonized bird 2.37 new birds will get colonized 
per day. 
1.4.2.2 Vertical transmission 
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 Vertical transmission of Campylobacter from hen to chick is still controversial. Many 
researchers have demonstrated the presence of Campylobacters in various segments of male and 
female reproductive tracts of poultry (Camarda, et al., 2000; Cox, et al., 2002a, 2002b, 2005; 
Cole, et al., 2004).  
 Contradictory to earlier studies, some researchers studied the possibility of vertical 
transmission of Campylobacter in poultry and their research findings indicate that vertical 
transmission of Campylobacter is very unlikely (Callicott, et al., 2006; Shane, 1992).  Further 
research needs to be done to strongly establish the possibility of vertical transmission in 
chickens. 
1.4.3 USDA Regulations 
 President Obama’s Food Safety Working Group (FSWG), formed in 2009, made some 
recommendations to improve the U.S food safety system (USDA-FSIS, 2010).  In an attempt to 
reduce the prevalence of Salmonella and Campylobacter in poultry products, the Food Safety 
Inspection Service (FSIS) developed the 3rd edition of compliance guide for the industry with 
recommendations for preharvest control of Salmonella and Campylobacter (USDA, 2010).  FSIS 
also revised the performance standards for Salmonella and proposed the first ever performance 
standards for Campylobacter for chilled carcasses at young chicken and turkey slaughter 
establishments (USDA-FSIS, 2010).  The new performance standards were announced on 10th 
May 2010, estimating that within 2 years of implementing the new standards, the number of 
illnesses due to Salmonella and Campylobacter could be reduced by 26,000 and 39,000 
respectively every year (USDA-FSIS, 2010).  The new standards were proposed based on the 
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information from the young chicken and turkey baseline studies (USDA-FSIS, 2008; USDA-
FSIS, 2009).  After careful analysis of the responses received during the 60 day comment period, 
starting July 2011, FSIS started implementing the new standards (USDA-FSIS, 2011).  FSIS 
Inspection program personnel (IPP) will collect and analyze samples from processing facility as 
per the procedure described in the baseline surveys (USDA-FSIS, 2008; USDA-FSIS, 2009).  
For any chicken processing plant to pass the Salmonella standards, the number of positives 
should not exceed 5 in a 51 sample set.  In case of turkey processing plants the number of 
Salmonella positives should not be more than 4 in 56 sample set.  For Campylobacter, the IPP 
will collect 1mL samples for direct plating and 30 mL enriched samples, which will be plated to 
detect low levels of contamination (NACMCF, 2007).  For chicken processing plants, 1mL 
samples were directly plated for both quantitative and qualitative purposes.  The 1mL sample 
results can detect up to 1 CFU/mL, whereas 30 mL enriched sample will be plated only if the 1 
mL samples fail to detect any Campylobacter.  Results from 30 mL samples are indicative of low 
levels of contamination with detection limit as low as 0.03 CFU/mL.  For any chicken  
processing plant to pass Campylobacter standards, a maximum of 8 positives out of a 51 sample 
set from 1mL results are allowed.  For turkey processing plant, 1 mL and 24 mL samples will be 
collected as per the procedure described by the Food Safety Advisory Committee (NACMCF, 
2007).  For any turkey processing plant to fulfill the Campylobacter standards, a maximum of 3 
positives from 56 sample set is allowed.  Although performance standards are based on 1mL 
results, the larger portion of the samples are still collected as they serve as a measure for the 
industry performance.  If any establishment fails to meet the performance standards in 3 
consecutive tests, FSIS will suspend inspection services and that suspension will remain until the 
establishment takes corrective action and submits a written assurance of the actions being taken.  
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Once FSIS has finished testing 90% of eligible establishments for two sets, the names of the 
establishments that do not meet the standards will be posted (USDA-FSIS, 2010). 
1.5 CONTROL OF CAMPYLOBACTER IN POULTRY 
1.5.1 Postharvest control strategies 
Many epidemiological studies report a high prevalence of Campylobacter on broiler carcasses 
(up to 98%) throughout the world.  Poultry processing involves steps like bleeding, scalding, 
defeathering, evisceration, washing and chilling.  Each of these steps may be associated with 
changes in the prevalence of Campylobacter counts on broiler carcasses (Guerin, et al., 2010).  
In conventional processing plants, broilers carcasses are immersed in large chilling tanks, which 
may serve as a potential source of cross-contamination for broiler carcasses (Wempe, et al., 
1983).  It has been estimated that proper handling can reduce carcass contamination to ˂4 log 
CFU/ carcass (Lindqvist and Lindblad, 2008).  Most studies demonstrate that processing reduces 
Campylobacter prevalence on broiler carcasses.  However, carcasses harboring high numbers of 
Campylobacter before processing also showed higher numbers after chilling.  It has been 
proposed that preharvest interventions may be more effective in reducing Campylobacter 
prevalence on broiler carcasses (Rosenquist, et al., 2003). 
1.5.2 Preharvest control of Campylobacter in poultry 
 Since poultry are the predominant sources of human infections many research findings 
indicate that reduction of Campylobacter in the vehicle i.e., poultry would greatly reduce the risk 
of human infections (Allos, 2001).  This was further supported by the findings of Rosenquist and 
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his colleagues (2003), who developed a risk model to study how different intervention strategies 
in poultry production and processing play a role in reducing the risk of human infections.  The 
findings indicate that a 2 log reduction of Campylobacter on chicken carcasses will result in 
reduction in human infections by 30 times (Rosenquist, et al., 2003).  According to this risk 
model, attempts to reduce cross contamination at slaughter and during food handling in kitchens 
showed a limited effect on reducing human incidence (Rosenquist et al., 2003).  This emphasizes 
the importance of reducing Campylobacter in poultry and thereby reducing human incidences 
(Allos, 2001; Lin, 2009).  Below are some of the preharvest control measures that may be used 
as potential strategies to reduce human infections. 
1.5.2.1 Biosecurity 
 Research has shown that adopting biosecurity measures such as washing hands, 
wearing protective clothing, clean foot ware, cleaning and disinfection of houses, provision of 
clean water, restricting the movement of vectors and farm personnel will reduce the prevalence 
of many infections in livestock and poultry (Shane, 1992; Vandeplas, et al., 2008).  Intervention 
studies done by researchers emphasize that implementation of strict on-farm biosecurity 
measures can potentially reduce the colonization of Campylobacter in broiler flocks (Gibbens, et 
al., 2001; Katsma, et al., 2007).  However, these measures can only reduce prevalence and do not 
guarantee complete elimination of Campylobacter from poultry (van de Giessen, et al., 1998; 
Vandeplas, et al., 2008).  Also, practical difficulties and costs associated with implementation of 
improved biosecurity measures further limits the application of this strategy to control 
Campylobacter in broilers (van de Giessen, et al., 1998; Fraser, et al., 2010).  A study conducted 
by Fraser and group (2010) indicated that implementation of biosecurity measures are strongly 
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influenced by the costs associated with adoption of such measures.  Hermans and colleagues 
(2011c) reviewed various intervention strategies to control Campylobacter, and concluded that 
biosecurity measures can potentially reduce colonization, but do not eliminate Campylobacter 
from poultry. 
1.5.2.2 Bacteriocins 
Bacteriocins are antibacterial proteins or peptides produced by bacteria that can kill or inhibit the 
growth of other closely related bacteria (Cotter, et al., 2005; Florey, 1946; Florey et al., 1949; 
Jacob et al., 1953; Cleveland, et al., 2001; Joerger, 2003; Montville and Kaiser, 1993; Stern, et 
al., 2006).  The first recorded evidence of bacterial antagonism was reported in 1877 (Pasteur 
and Joubert, 1877).  Pasteur and Joubert (1877) reported that co-inoculating anthrax bacterium 
with some “common bacteria” can potentially reduce or inhibit the growth of anthrax bacillus.  
Later research suggested that the inhibition in the presence of “common bacteria” could be due 
to production of bacteriocins by these bacteria (Tagg, et al., 1976).  Jacob and his colleagues 
(1953) first proposed the name bacteriocin to the antibacterial proteins of bacterial origin. 
Earlier research on bacteriocins emphasized bacteriocins produced by gram negative 
bacteria (eg. colicins, Nisin etc.,), especially the members of Enterobacteriaceae family.  
However, both gram negative and gram positive bacteria have been reported to produce 
bacteriocins.  It has been proposed that bacteriocins act by adsorbing to the surface receptors of 
susceptible bacteria and inhibit their growth by altering the membrane potential, inducing pore 
formation and causing leakage of cellular contents (Daw and Falkiner, 1996; Cleveland, et al., 
2001).  Some bacteriocins were reported to produce inhibitory action by interfering with the 
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protein or nucleic acid biosynthesis (Foulds, 1971).  Contrary to the conventional belief that 
bacteriocins affect the growth of closely related bacteria, some bacteriocins have been reported 
to possess a broad spectrum of activity against a wide range of organisms.  For example, 
bacteriocins like nisin Z, produced by Lactococcus lactis; enterocins (E-760) produced by 
Enterococcus spp. and reuterin produced by Lactobacillus reuteri have demonstrated broad 
spectrum activity against a wide range of bacterial pathogens (Rodríguez, et al., 2003; Kuwano, 
et al., 2005; Corr, et al., 2007; Line, et al., 2008; Svetoch, et al., 2011; Messaoudi, et al., 2012).  
Research showed that oral administration of bacteriocins produced by gram positive bacteria 
such as Bacillus circulans, Paenibacilluspolymyxa (B 602) and Lactobacillus salivarius 
produced a significant reduction in Campylobacter colonization in broilers (Stern, et al., 2005, 
2006; Svetoch, et al., 2005; Svetoch and Stern, 2010).  Similarly, Cole and co-workers (2006) 
demonstrated that feeding purified bacteriocins in microencapsulated form can reduce C. coli to 
below the detection limit in turkeys.  Unfortunately, the narrow spectrum of activity, 
susceptibility to proteolytic enzymes of the gastrointestinal tract and possible development of 
resistance to bacteriocins may limit the use of bacteriocins to reduce intestinal pathogens in 
poultry (Connerton and Connerton, 2005; Lin, 2009).  Recent studies conducted by Hoang and 
group (2011a, 2011b) studied the in vitro and in vivo stability and development of resistance to 
bacteriocins.  These studies reported that there is a limited possibility for Campylobacter to 
develop resistance against the tested bacteriocin.  These experiments were conducted under 
controlled conditions with one strain of Campylobacter and one bacteriocin.  However further 
research should be done to explain the role of complex interactions occurring in commercial 
settings, the influence of selection pressure and possible emergence of mutants resistant to the 
bacteriocins.  
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Further, bacteriocins need to be chemically characterized and should be approved by the 
FDA for use in foods.  So far nisin is the only bacteriocin approved by the U.S. Food and Drug 
Administration for use in cheese products as an antimicrobial (21 CFR 184.1538).  Though 
manufacturing companies can attribute the GRAS status to any new bacteriocin, they should be 
able to scientifically prove the efficacy and justify the application of such bacteriocin (Connerton 
and Connerton, 2005). Additionally, the costs associated with extraction and purification of 
bacteriocins further limits their use in poultry industry. 
1.5.2.3 Bacteriophages 
Bacteriophages are viruses that infect and kill bacteria (Duckworth and Gulig, 2002; 
Doyle and Erickson, 2006).  Bacteriophages were first discovered independently by two 
European scientists Federick Twort (1915) and Félix d’Herelle (1917).  Bacteriophages act by 
recognizing specific cell surface receptors of bacteria, inject their DNA into the host, and take 
over host cell machinery for rapid multiplication and release by lysis of the host bacterium 
(Duckworth and Gulig, 2002; Doyle and Erickson, 2006).  Two types of bacteriophages exist in 
nature, temperate and lytic phages.  Of these two phage types, lytic phages were often used for 
therapeutic purposes. Lytic phages are preferred over temperate phages, as they are highly 
specific, can be readily isolated from the same environment as the host and can effectively kill 
the host bacteria (Duckworth and Gulig, 2002; Doyle and Erickson, 2006). 
d’Herelle in his book ‘The bacteriophage and its behavior’ described the therapeutic 
potential of bacteriophages in treating many diseases (d’Herelle, 1926).  Later, many researchers 
successfully demonstrated the use of phages to control pathogens such as E. coli (Barrow, et al., 
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1998; Huff, et al., 2005) and Salmonella (Fiorentin, et al., 2005; Higgins, et al., 2005).  
Campylobacter specific phages have also been isolated and studied for their efficacy in reducing 
Campylobacter colonization in broiler chickens (Atterbury, et al., 2003; Loc Carrillo, et al., 
2005; Wagenaar, et al., 2005; El-Shibiny, et al., 2009; Carvalho, et al., 2012).  Wagenaar and 
associates (2005) studied both prophylactic and therapeutic efficacy of phages in reducing 
Campylobacter colonization in broiler chickens.  These studies concluded that prophylactic 
treatment using bacteriophages will only delay colonization but not reduce Campylobacter in 
comparison to the control.  On the other hand, therapeutic use of bacteriophage showed up to 3 
log reduction in Campylobacter for a few days following administration.  Several other studies 
also reported similar reduction in Campylobacter for first few days following phage therapy (El-
Shibiny, et al., 2009; Carvalho, et al., 2010).  These studies indicate that therapeutic use of 
bacteriophages, especially on the day before slaughter would be more practical and effective in 
reducing Campylobacter counts on chickens and thus could be an effective strategy to reduce the 
risk to humans (Wagenaar, et al., 2005).  
 Despite the successful demonstration of phages to reduce many enteric pathogens, 
possible development of phage resistance, transmission of antibiotic and/or virulence genes 
between bacteria limit the potential use of bacteriophages in controlling bacterial diseases 
(Duckworth and Gulig, 2002; Janež and Loc-Carrillo, 2013).  Since phages themselves are 
foreign to the body, it is very likely that an immune response against phages may render them 
ineffective (Duckworth and Gulig, 2002).  Moreover, narrow host range (due to high specificity) 
and consumer acceptability further limit the use of bacteriophages in food animals (Janež and 
Loc-Carrillo, 2013).  
 24 
 
1.5.2.4 Organic acids 
Organic acids are weak acids that are widely distributed in nature.  Organic acids are 
GRAS and approved for use in foods intended for both human and animal consumption (Theron 
and Rykers, 2010; FSIS, 2013).  Organic acids are known to possess antibacterial and antifungal 
properties and are extensively used in food preservation to increase the shelf life (Dibner and 
Buttin, 2002; Theron and Rykers, 2010).  Organic acids are also known to have the capacity for a 
growth promotion effect and are extensively used in pig and poultry production (Patten and 
Waldroup, 1988; Dibner and Buttin, 2002).  They are known to possess antimicrobial activity 
against many foodborne pathogens (Chaveerach, et al., 2002; Dibner and Buttin, 2002; Ricke, 
2003; Jarquin, et al., 2007).  Many researchers successfully demonstrated that inclusion of 
organic acids in drinking water can reduce pathogens such as E. coli, Salmonella enterica, 
Campylobacter, Staphylococcus aureus (Byrd, et al., 2001; Chaveerach, et al., 2002, 2004a; 
Parker, et al., 2007).  Many authors demonstrated the efficacy of organic acids on Salmonella in 
vitro and in vivo (Van Immerseel, et al., 2003; Johny, et al., 2009).  Earlier studies from our 
laboratory successfully demonstrated that prophylactic and therapeutic supplementation of 0.7% 
caprylic acid, a medium chain fatty acid, in feed produced a 2-3 log reduction in Campylobacter 
(Solis de Los Santos, et al., 2008a, 2008b, 2009, 2010).  However, the results were not repeated 
when a sodium salt of caprylic acid was supplemented in feed or water (Metcalf, et al., 2011; 
Hermans, et al., 2010, 2012).  Contradictory results reported by various researchers and failure of 
encapsulated organic acids to show consistent reduction (Van Immerseel, et al., 2004) further 
emphasize the need to develop novel and effective strategies that can consistently reduce 
Campylobacter colonization in broiler chickens.  
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1.5.2.5 Plant extracts 
With the increasing consumer preference towards natural products, many researchers 
focused on using plant based products as potential alternatives to antibiotic growth promoters 
(Gauthier, 2003).  Plant extracts, mainly essential oils obtained from various sources such as bay, 
cinnamon, clove, garlic, oregano, peppermint, rosemary, sage, thyme and many more have been 
extensively studied for their antimicrobial properties (Deans and Ritchie, 1987; Cosentino, et al., 
1999; Dorman and Deans, 2000; Friedman, et al., 2002; Burt, 2004; Gill and Holley, 2004; 
Prabuseenivasan, et al., 2006; Si, et al., 2006; Cox and Markham, 2007; Kollanoor Johny, et al., 
2010; Brenes and Roura, 2010; Stefanakis, et al., 2013; Venkitanarayanan, et al., 2013).  
Extensive research has been done on plant essential oils and many researchers demonstrated the 
in vitro efficacy of these compounds against the common foodborne pathogens (Friedman, et al., 
2002; Kollanoor Johny, et al., 2010; Upadhyay, et al., 2013; Upadhyaya, et al., 2013).  Plant 
essential oils are generally regarded as safe (GRAS) and are approved for use in food animals by 
the FDA (21CFR182.20, FDA, 2013).  However, many factors may influence the in vivo efficacy 
of essential oils.  Factors such as chemical composition of essential oils, concentration of active 
compound, pH, composition and moisture content of feed may affect the efficacy of essential oils 
(Shelef, et al., 1984; Juven, et al., 1994; Tassou, et al., 1995; Gauthier, 2003; Si, et al., 2006; 
Santiesteban-Lopez, et al., 2007).  Essential oils such as eugenol and trans-cinnamaldehyde 
showed a significant reduction in Salmonella colonization in broiler chickens (Kollanoor-Johny, 
et al., 2012).  However the same compounds, eugenol and trans-cinnamaldehyde did not 
demonstrate a similar reduction in Campylobacter colonization in broiler chickens (Metcalf, 
2008; Hermans, et al., 2011a).  Studies conducted in our laboratory with other plant extracts such 
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as thymol, carvacrol, cranberry extract did not demonstrate significant reductions in 
Campylobacter colonization (Arsi, 2011; Woo-Ming, 2012).  Even though plant derived 
compounds showed promising results in inhibiting Campylobacter in vitro, further studies are 
needed to develop an ideal dose-delivery system of an appropriate compound to produce 
significant reduction in Campylobacter in broiler chickens. 
1.5.2.6 Vaccination 
 Vaccination has been considered as one of the most effective strategy to control 
pathogenic infections.  Unfortunately, no commercial vaccines are available to control 
Campylobacter infections in poultry.  Campylobacter naturally colonizes and survives as a 
commensal in the G.I tract of poultry.  It has been suggested that factors essential for 
colonization (flagellin, CadF, CiaB, major outer membrane proteins, lipopolysaccharide), could 
be potential targets for a vaccine (Ziprin, et al., 2001; de Zoete, et al., 2007; Lin, 2009).  
Research has been done to develop vaccines using killed whole cell vaccines, live attenuated 
vaccines, flagellum based vaccines and recombinant vaccines have shown limited success in 
controlling Campylobacter colonization (de Zoete, et al., 2007; Hermans, et al., 2011b; 
Laniewski, et al., 2013).  Some researchers attempted to develop vaccines by expressing 
Campylobacter antigens on attenuated Salmonella strains with varying degrees of success 
(Wyszyńska, et al., 2004; de Zoete, et al., 2007; Laniewski, et al., 2013). 
Recent studies reported promising results with some degree of success in developing a 
vaccine to protect against Campylobacter infections (Layton, et al., 2011; Annamalai, et al., 
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2013).  However, further research needs to be done to develop a vaccine that is cost effective and 
practical to administer under commercial settings. 
1.6 PROBIOTICS AND PREBIOTICS FOR THE PREHARVEST CONTROL OF 
CAMPYLOBACTER IN POULTRY 
1.6.1 Probiotics 
The word probiotic in Greek means “for life” and the beneficial effects of probiotics on 
human health has been widely reported (Gibson and Fuller, 2000; Salminen, et al., 2010; Salim, 
et al., 2013; Serban, 2013).  During early 1900’s researchers such as Tissier (1906) and 
Metchnikof (1907) published on the beneficial effects of probiotic bacteria on human health.  
Metchnikoff in his book “The Prolongation of Life: Optimistic studies” explained that milk 
fermenting microbes produce lactic acid, making the environment hostile for growth of 
pathogens.  Lilly and Stillwell (1965) first used the term ‘probiotic’ to describe the growth 
promoting substances secreted by a protozoan that stimulates the growth of another.  Since then, 
many scientists redefined probiotics as, “organisms and substances that contribute to intestinal 
microbial balance” (Parker, 1974); or “foods that contain live bacteria which are beneficial to 
health (Salminen, et al., 1998).  The widely accepted definition of probiotic as given by Fuller is 
“live microorganisms which when administered in adequate amounts can confer beneficial 
effects on host health” (Fuller 1989). 
The exact mechanisms by which probiotic bacteria confer health benefits are unclear.  
However, several researchers proposed the possible mechanism of action of probiotics (Fuller, 
1989; Fooks, et al., 1999; Salminen, et al., 2010).  Accordingly probiotics may produce 
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beneficial effects by competing with the pathogens for binding sites, nutrients, or by producing 
antimicrobial compounds (Fuller, 1989).  Also, it has been reported probiotics may possibly 
improve barrier functions, prevent food allergies and may possibly play a role in prevention and 
treatment of GI tumors (Fuller, 1989; Ouwehand, et al., 2005; Sanders and Marco, 2010; Serban, 
2013). 
A wealth of research has been done on probiotics and it has been suggested that an ideal 
probiotic should meet the following criteria: 1) the probiotic should contain viable cells that are 
nonpathogenic and nontoxic; 2) should resist the hostile conditions prevailing in the stomach and 
small intestine before reaching the target site; 3) should provide protection from pathogens by 
immune modulation and competitive inhibition (Fuller, 1989; Chateau, et al., 1993; Gibson and 
Fuller, 2000).  Over the years researchers demonstrated the in vitro and in vivo efficacy of 
several probiotics to inhibit enteric pathogens such as Salmonella, Campylobacter, and E. coli 
(Fooks and Gibson, 2002; Chaveerach, et al., 2004b; Santini, et al., 2010).  However, orally 
provided probiotics may not be maintained in the GI tract for longer periods and, hence, it has 
been suggested that continuous supply of probiotics may be needed to produce the desired effect 
(Kaur, et al., 2002).  To overcome this limitation, some researchers exploited the phenomenon of 
competitive exclusion. 
1.6.2 Competitive exclusion (CE) 
 The concept of competitive exclusion was first proposed by Nurmi and Rantala.  Nurmi 
and Rantala (1973) successfully demonstrated the protective effect of undefined cultures against 
Salmonella infections in young chickens.  As per the Nurmi concept, day of hatch birds are 
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inoculated with adult microflora, which then colonize in the GI tract and offer protection against 
pathogens that they may encounter in future (Nurmi and Rantala 1973; Pivnick and Nurmi 1982; 
Nurmi, et al., 1992; Schneitz, et al., 1992;).  Competitive exclusion products compete with 
pathogens by occupying their ecological niche and by making the luminal environment hostile 
via the production of volatile fatty acids (increase luminal pH) and antibacterial substances such 
as bacteriocins (Barnes, et al., 1980; Pivnick and Nurmi 1982; Nurmi, et al, 1992; Corrier, et al., 
1994; Mead, 2000).  Subsequently, several researchers demonstrated the effectiveness of 
undefined cultures to control Salmonella in chickens (Aho, et al., 1992; Palmu and Camelin, 
1997).  With the raising concerns about the safety of undefined cultures, later research mainly 
focused on developing defined cultures to ensure safety and effectively protect the host health 
from pathogens (Impey, et al., 1982; Schoeni and Wong, 1994; Bielke, et al 2003).   
Competitive exclusion phenomenon was mainly developed to protect young chickens 
from Salmonella infections.  Later, the concept has been extended to protect against many enteric 
pathogens in other species (Hakkinen and Schneitz, 1996; Soerjadi, et al., 1981; Soerjadi-Liem, 
et al., 1984; Hume, et al., 1998a, 1998b; Stern, et al., 2001).  Most of the CE products with 
efficacy against Salmonella failed to demonstrate similar effect against Campylobacter (Stavric 
and D’Aoust, 1993; Mead, 2000).  To protect against Campylobacter, researchers developed CE 
products with efficacy against Campylobacter (Aho, et al., 1992; Schoeni and Doyle, 1992; 
Schoeni and Wong, 1994; Stern, et al., 2001b; Ghareeb, et al., 2012; Aguiar, et al., 2013).  
However, most of the competitive exclusion products developed against Campylobacter 
demonstrated efficacy in vitro, but showed limited success in vivo (Santini, et al., 2010; Robyn, 
et al., 2012; Aguiar, et al., 2013).  This reiterates the need to develop novel products or strategies 
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to inhibit Campylobacter colonization in poultry.  One possible strategy is to supplement dietary 
prebiotics along with the probiotic bacteria. 
1.6.3 Prebiotics 
 A prebiotic is a “non-digestible food ingredient that beneficially affects the host by 
improving its intestinal microbial balance” (Gibson and Roberfroid, 1995).  Food ingredients 
should meet the following criteria to be classified as a prebiotic: 1) should not be metabolized in 
the stomach or small intestine and reach the large intestine intact 2) should be selectively 
metabolized by one or a limited number of beneficial bacteria and stimulate their growth and/or 
activity in the lower intestine; and 3) should modulate the gut microbiome and induce beneficial 
effects on host health (Gibson and Roberfroid 1994; Gibson and Fuller 2000).  It has been 
indicated that prebiotic supplementation in feed is cheaper, less risky and can selectively enhance 
the growth of beneficial microflora and thereby protect the host from enteric pathogens 
(Patterson and Burkholder, 2003; Mac Farlane et al., 2006).  Reportedly non-digestible 
oligosaccharides such as inulin, lactulose, galactooligosaccharides, glucooligosaccharides, 
fructooligosaccharides (FOS), and soybean oligosaccharides are commonly used as feed 
supplements to improve the host health and performance.  Even though, prebiotics alone can 
induce beneficial effects on host health, synbiotics (combination of probiotics and prebiotics) are 
proposed to be more efficacious than prebiotics or probiotics in producing the desired response 
(Serban, 2013). 
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Figure 1. Scanning electron micrograph of Campylobacter (Pead, 1979). 
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Table 1: Human incidence of campylobacteriosis/100,000 people from all over the world 
Country Incidence/ 100,000 References 
Czech republic 195 Bardoň, 2013; Havelaar, et al., 2013 
New Zealand 161.5 Sears, et al., 2011 
Canada 30.2 CMAJ, 2007 
Ireland 42.6 FSAI, 2011 
United States 14.3 CDC, 2013b 
Iceland 38.62 EFSA, 2013b 
Norway 61.07 EFSA, 2013b 
Switzerland 100.80 EFSA, 2013b 
Belgium 70.46 EFSA, 2013b 
Denmark 73.01 EFSA, 2013b 
Finland 79.29 EFSA, 2013b 
Germany 86.62 EFSA, 2013b 
Hungary 61.30 EFSA, 2013b 
Ireland 54.30 EFSA, 2013b 
Lithuania 34.64 EFSA, 2013b 
Luxembourg 137.54 EFSA, 2013b 
United Kingdom 115.44 EFSA, 2013b 
Sweden 87.24 EFSA, 2013b 
Spain 47.4 EFSA, 2013b 
Slovania 48.68 EFSA, 2013b 
Slovakia 83.99 EFSA, 2013b 
Netherlands 50.89 EFSA, 2013b 
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Table 2: Percent prevalence of Campylobacter in poultry flocks from various countries 
across the world. 
  
Country Prevalence in poultry flocks Reference 
Denmark 74.6% (Jore, et al., 2010) 
Iceland 59.5% Jore, et al., 2010 
Norway 74.1% Jore, et al., 2010 
Sweden 81.8% Jore, et al., 2010 
Netherlands 58.9% Jore, et al., 2010 
Czech Republic 63.4% Bardoň, 2013; EFSA, 2013b 
Ireland 80.6% EFSA, 2013b 
Spain 68.4% EFSA, 2013b 
Slovania 88-93% Bardoň, 2013 
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Table 3: Percent prevalence of Campylobacter in retail poultry reported from different 
countries 
 
 
 
 
 
 
 
 
 
  
Country Prevalence in retail poultry Reference 
United States 71.5% Suzuki and Yamamoto, 2009 
Canada 57.7% Suzuki and Yamamoto, 2009 
Czech Republic 75% Bardoň, 2013 
Spain 75.8% EFSA, 2013b 
Poland 82.7% EFSA, 2013b 
Ireland 52.9% EFSA, 2013b 
Hungary 41.3% EFSA, 2013b 
Argentina 92.9% Suzuki and Yamamoto, 2009 
Italy 80.0% Suzuki and Yamamoto, 2009 
Africa 73.1% Suzuki and Yamamoto, 2009 
Asia 60.3% Suzuki and Yamamoto, 2009 
New Zealand 89.1% Suzuki and Yamamoto, 2009 
Japan 58.8% Suzuki and Yamamoto, 2009 
Australia 100% Suzuki and Yamamoto, 2009 
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Chapter 2 
EFFECT OF SELECTED PROBIOTIC AND PREBIOTIC COMBINATIONS IN 
REDUCING CAMPYLOBACTER COLONIZATION IN BROILER CHICKENS. 
K. Arsi1, A. M. Donoghue2, A. Woo-Ming1, H. R. Arambel1, P. J. Blore1 and D. J. Donoghue1 
1Poultry Science Department, University of Arkansas, Fayetteville, Arkansas 72701 
2Poultry Production and Product Safety Research Unit, Agricultural Research Service, 
USDA, Fayetteville, Arkansas 72701. 
2.1 ABSTRACT  
Campylobacter is one of the leading causes of foodborne illness worldwide and human 
illnesses are often associated with consumption of contaminated poultry or poultry products.  
One of the strategies to reduce Campylobacter colonization in poultry is by use of probiotics.  
One hundred seventeen GRAS (Generally Regarded as Safe) bacteria were isolated from healthy 
birds and evaluated for efficacy against Campylobacter, in vitro.  A soft agar overlay technique 
was used to measure anti-Campylobacter activity of these isolates based upon the diameter of the 
zone of inhibition around the bacterial colony.  Twenty six such isolates with in vitro efficacy 
against Campylobacter were tested in vivo in 3 separate trials.  For the in vivo trials, bacterial 
isolates were administered orally to chicks on the day of hatch.  On day 7, chicks were orally 
challenged with a 4 strain mixture of wild type C. jejuni (~107 CFU/mL) and on day 14 cecal 
samples were collected for Campylobacter enumeration.  Out of 26 isolates with in vitro 
efficacy, 3 isolates produced a reduction in cecal Campylobacter counts (1-2 logs).  In an effort 
to improve the efficacy of these 3 isolates, two prebiotics (Fructoligosaccharide/FOS or 
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Mannanoligosaccharide/MOS) were added to the feed in follow up trials during the entire 14 day 
trials.  None of the isolates nor the FOS doses tested (0.125%. 0.25% or 0.5%) or the 
combination of individual isolates with selected FOS doses reduced cecal Campylobacter counts.  
When the isolates were tested with MOS (0.04%, 0.08% and 0.16%), combination of isolate 3 
with 0.04% MOS in feed demonstrated a 3-log reduction in cecal Campylobacter counts.  The 
results of this study indicate that the selection and administration of bacterial isolates in 
combination with selected prebiotics may reduce enteric Campylobacter counts in preharvest 
poultry, however few treatments are effective.   
KEYWORDS: Campylobacter jejuni, probiotic, FOS, MOS, chicken. 
2.2 INTRODUCTION 
 Campylobacter is a leading cause of foodborne illness in the United States and across the 
world (CDC, 2010; WHO, 2011), with 400 million illnesses annually worldwide (Rollwagen, et 
al., 1993).  Campylobacter is estimated to cause 0.8 million illnesses each year in the United 
States (Scharff, 2012) and cost $1.7 billion annually (Batz, et al., 2012; Hoffmann, et al., 2012).  
Two species, C. jejuni and C. coli are usually associated with Campylobacter illness in humans, 
of which the majority of illnesses are caused by C. jejuni (Butzler, et al., 1973; Phillips, 1995; 
Debruyne, et al., 2008; EFSA, 2013).  Case control studies have demonstrated that the majority 
of human infections are associated with consumption or improper handling of poultry (Skirrow, 
1982; Kapperud, et al., 2003; Stafford, et al., 2008; Danis, et al., 2009).  Therefore, a reduction 
or elimination of Campylobacter from poultry would greatly reduce the human incidence 
(Rosenquist, et al., 2003).  Many intervention strategies have been evaluated in an effort to 
control Campylobacter in poultry, but none have been successful in eliminating this bacterium 
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(Wagenaar, et al., 2005; Cole et al., 2006; de Zoete, et al., 2007; Solis de lo Santos et al., 2008, 
2009; Vandeplas, et al., 2008; Santini, et al., 2010; Hermans, et al., 2011).  In this study we 
attempted to reduce/inhibit enteric Campylobacter colonization in chickens by developing a 
probiotic culture.  For this we collected and identified bacterial isolates which are Generally 
Regarded as Safe (GRAS, FDA, 2013b).  Isolates with GRAS status are recognized as safe to 
immediately administer to birds without the cost and delays associated with regulatory approval 
(FDA, 2013a).  Probiotics are “live microorganisms which when administered in adequate 
amounts can confer beneficial effects on host health” (Fuller 1989).  Probiotics proved to be an 
effective strategy to control pathogens such as Salmonella, E. coli and Listeria (Soerjadi, et al., 
1981; Impey, et al., 1982; Hakkinen and Schneitz, 1996; Hume, et al., 1998a, 1998b; Stern, et 
al., 2001; Fooks and Gibson, 2002; Bielke, et al 2003; Zhang et al., 2007b). 
The objective of this study was to develop probiotic isolates that can inhibit 
Campylobacter colonization in broilers chickens.  Studies were conducted to isolate GRAS 
bacteria from healthy chickens and evaluate their efficacy to inhibit Campylobacter in vitro.  The 
isolates with in vitro anti-Campylobacter activity were selected and tested in vivo.  Follow up 
studies were conducted to enhance the in vivo efficacy of selected isolates by additionally 
supplementing a prebiotic in the feed. 
2.3 MATERIALS AND METHODS 
2.3.1 Isolation and identification of probiotic bacteria 
 Probiotic bacteria were isolated from the cecal contents of healthy birds of different age 
groups according to the procedure of Aguiar and co-workers (2013).  Briefly, the procedure 
involves collection of ceca from healthy chickens under aseptic conditions.  Cecal contents were 
 61 
 
then squeezed into sterile tubes and diluted with Buffed Phosphate Diluent (BPD). Up to 3 
dilutions were made using BPD (1:10, 1:100 and 1:1000) and 100µL of each dilution was plated 
on blood agar plates (BAP, Difco™ Becton Dickinson and company, MD).  Another set of 
dilutions were plated on deMan, Rogosa and Sharpe Agar (Difco™ Becton Dickinson and 
company, MD). Both the plates were incubated at 37°C for 24 hours.  Isolated colonies from 
each plate were picked and streaked again on fresh BAP and incubated as described above.  This 
procedure was repeated until pure cultures were obtained.  Initial identification of isolated 
colonies was done using Gram’s staining.  Further identification was done using Biolog® system 
(Biolog®, Hayward, CA) as per the procedure previously described by our laboratory (Aguiar, et 
al., 2013).  Glycerol stock solutions of the isolates, which were identified as GRAS by FDA 
(2013b), were prepared and stored at -80°C (Aguiar, et al., 2013; Bhaskaran, et al., 2011; Bielke, 
et al., 2003). 
2.3.2 Screening for in vitro anti-Campylobacter activity of the isolates 
 The in vitro screening for anti-Campylobacter activity was done using a soft agar overlay 
technique (Gratia, 1936; Aguiar et al., 2013).  The isolates were first grown in 5 mL of Tryptic 
soy broth (TSB, BBL® Becton Dickinson and Company, MD) and incubated at 37°C for 24 
hours. From the broth 100µL of culture was inoculated in the middle of a Tryptic Soy Agar 
(TSA, Difco™ Becton Dickinson and company, MD) plate and incubated at 37°C for 24 hours.  
Simultaneously Campylobacter strains were grown on Campylobacter Enrichment Broth (CEB, 
Neogen corporation, MI) and 100µL of 24 hour old Campylobacter culture was added to 2 mL of 
soft agar (0.65% agar) and carefully overlaid on the TSA plate with probiotic isolate in the 
middle (Aguiar, et al., 2013; Zhang, et al., 2007a).  The TSA plate with soft agar was incubated 
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under microaerophilic conditions at 42°C for 48 hours.  The isolates with in vitro anti-
Campylobacter activity show a clear zone of inhibition around the probiotic colony (Figure 1).  
The bigger the diameter of the zone, the greater the inhibitory activity.  The isolates with the 
greatest inhibitory activity against Campylobacter were selected for evaluation of in vivo 
efficacy against Campylobacter colonization in broiler chickens. 
2.3.3 In vivo studies 
2.3.3.1 Experimental animals and housing 
For all the in vivo studies, day of hatch commercial broiler chicks were weighed at the 
beginning and at the end of each trial.  Chicks were raised on floor pens with pine shavings and 
ad libitum access to both feed and water for the 14 day trial period. 
2.3.3.2 Experimental design 
During the first 3 trials, 26 isolates were evaluated for their in vivo efficacy against 
Campylobacter.  In trials 1 and 2, a total of 100 birds were randomly divided into 10 treatment 
groups (n=10/treatment) with a Campylobacter control group (Campylobacter, no isolate) and 9 
groups testing the efficacy of single bacterial isolate (a total of 18 separate isolates were tested, 9 
in trial 1, another 9 in trial 2).  In the third trial, a total of 90 birds (n=10/treatment) were 
randomly divided into 9 treatment groups (1 Campylobacter control group and 8 groups, each 
receiving single bacterial isolate).  From these 3 trials, 3 isolates (Isolate 1, 2 and 3) with in vivo 
efficacy against Campylobacter were selected and tested in trials 4 and 5. 
In trial 4, a total of 160 birds were divided into 16 treatment groups with 10 birds per 
treatment. Treatments include a Campylobacter control (Campylobacter, no isolate, 0% FOS), 
isolate controls (Campylobacter, Isolate 1, 2 or 3, 0% FOS), selected doses of 
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Fructooligosaccharides/FOS (BOC Sciences, NY), 0.125%, 0.25%, 0.5% in feed, and the 
combination of individual isolate with selected dose of FOS. 
For trial 5, the experimental design was similar to trial 4 (total 160 birds with 16 
treatments, n=10/treatment) except Mannanoligosaccharide/MOS (Actigen™, Alltech, Inc, KY) 
was fed to birds instead of FOS.  In trial 5, treatment groups include a Campylobacter control 
(Campylobacter, no isolate, 0% MOS), isolate controls (Campylobacter, isolate 1, 2 or 3, 0% 
MOS), MOS controls (0.04%, 0.08% and 0.16%) in feed, and the combinations of MOS and 
individual isolates. 
2.3.3.3 Bacterial Strains and dose 
 During each trial, all treatment groups, except for the Campylobacter control, were orally 
gavaged with 0.25 mL of specific bacterial isolate containing approximately 1x107CFU/mL of 
bacterial isolate on day 1.  On day 7, all the birds were orally gavaged with a 4 strain mixture of 
wild type Campylobacter containing approximately 1x107CFU/mL organisms.  On day 14, all 
the birds were euthanized and ceca were collected for Campylobacter enumeration. 
2.3.3.4 Campylobacter enumeration 
 Cecal Campylobacter counts were determined as per the procedure described in earlier 
studies (Bhaskaran, et al., 2011; Aguiar, et al., 2013).  Ceca were collected on day 14 and the 
contents were serially diluted (1:10) with BPD.  Each dilution was then plated on Campylobacter 
Line Agar (CLA, Line, 2001) and incubated under microaerophilic conditions for 48 hours at 
42°C.  Suspected Campylobacter colonies were confirmed by latex agglutination test (LATEX: 
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CAMPY [jcl]™ Test Kit, Scimedx corporation, NJ) and further confirmation was done with api® 
Campy (bioMérieux Vitek, Inc, MO). 
2.3.4 Statistical Analysis  
 Data were analyzed using PROC GLM procedure of SAS (SAS, 2011).  Campylobacter 
colonies were enumerated and the counts for CFU/mL were then log transformed before analysis 
to achieve homogeneity of variance (Byrd, et al., 2003).  Treatment means were partitioned by 
least square means analysis and a probability of P ˂ 0.05 was considered for statistical 
significance. 
2.4 RESULTS 
 For this study 117 GRAS bacteria were isolated from healthy chickens.  Of these 117 
isolates, 48 isolates inhibited Campylobacter in vitro, as determined by the soft agar overlay 
technique (data not shown).  When 26 such isolates with greatest inhibitory activity in vitro were 
tested in vivo, only 3 isolates (isolates 1, 2 and 3) showed approximately a 1-2 log reduction in 
Campylobacter compared to the control (Figure 2).  In the last two trials utilizing both bacterial 
isolates and FOS or MOS in the feed, none of the individual isolates nor the FOS or MOS 
treatments by themselves showed any reduction in Campylobacter (Tables 1 and 2).  However, 
in trial 5, the treatment group which received isolate 3 and 0.04% MOS in feed showed a 3 log 
reduction of Campylobacter compared to the control group (Table 2).  Even though FOS 
treatments did not reduced Campylobacter, increases in body weight gain were seen with 
0.125% FOS and its combinations with the 3 isolates, combination of 0.25% FOS and isolate 2, 
0.5% FOS and the combinations of 0.5% FOS and isolate 3 as compared with the birds fed 
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control diet (Table 3).  However, MOS treatments or its combinations with probiotic isolates did 
not show an improvement in body weight gain compared to the control (Table 4).  Additionally, 
birds fed 0.16% MOS and its combination with isolate 1 and 2 did not achieve as much gain as 
the controls. 
2.5 DISCUSSION 
Campylobacter naturally colonize in high numbers (up to 109 CFU/mL) in the mucosal 
crypts of the avian ceca (Beery, et al., 1988).  Isolating GRAS bacteria from the chicken ceca 
and orally inoculating such bacteria into the poultry early in life (day 1) may initiate colonization 
of the ceca and inhibit the colonization of Campylobacter.  The exact mechanism by which the 
probiotic bacteria produce beneficial effects is not fully understood.  It has been proposed that 
probiotic bacteria may inhibit pathogens by competing for adhesion sites and nutrients (Pivnic 
and Nurmi, 1982; Callaway, et al., 2008).  Other mechanisms by which they produce beneficial 
effects include production of volatile fatty acids and antimicrobial substances (Barnes, et al., 
1980; Nurmi, et al., 1992; Stavric, 1992; Corrier, et al., 1994; Callaway, et al., 2008).  In the 
present study, when 26 GRAS isolates with in vitro Campylobacter activity were tested in vivo, 
only 3 isolates showed a 1-2 log reduction in Campylobacter (Figure 2).  However, these isolates 
reduced Campylobacter only in 1 out of 3 trials.  In follow up trials, the 3 efficacious GRAS 
isolates were supplemented with a prebiotic in order to enhance their in vivo effect.  Studies have 
demonstrated that prebiotics, used alone or in combination with probiotics, provide beneficial 
effects on host health by selectively stimulating the growth and/or activity of beneficial 
microflora (Gibson and Roberfroid 1995; Gibson and Fuller 2000).  We selected one of the most 
studied prebiotic compounds, FOS for our initial study (Bailey, et al., 1991; Gibson and Fuller, 
 66 
 
2000).  Fructooligosaccharides are non-digestible carbohydrates present in many plant sources 
such as wheat, onion, banana, garlic and chicory (Niness, 1999).  Research has demonstrated that 
FOS can induce beneficial effects in the host by selectively promoting the growth of 
Bifidobacteria and Lactobacillus and decreasing the numbers of pathogens such as Clostridia 
and E. coli (Janardhana, et al., 2009; Kim, et al., 2011).  Also, it has been shown to produce 
immunomodulatory effects by producing short chain fatty acids (SCFA) like butyrates 
(Janardhana, et al., 2009).  However, our studies with FOS did not demonstrate a reduction in 
Campylobacter in the ceca of broiler chickens.  Similar inconsistencies on the efficacy of FOS 
supplementation on Salmonella colonization have been reported (Chambers, et al., 1997; Fukata, 
et al., 1999; Oyarzabal and Conner, 1996; Ten Bruggencate, et al., 2003).  It is possible that the 
birds raised under controlled conditions may not have the same microflora as commercial poultry 
which would efficiently utilize FOS and produce the target effect in the host.  Also, there are 
reports that higher than optimum doses of FOS in the diet are associated with increased gas 
production and poor performance (Kim, et al., 2011).  Since, we could not bring about the 
desired reduction in Campylobacter colonization using FOS in the diet, we evaluated another 
potential prebiotic compound, MOS, in our next study.   
Mannanoligosaccharide is derived from the cell wall of yeast, Saccharomyces cerevisiae 
(Miguel, et al., 2004).  Research has shown that dietary inclusion of MOS has 
immunomodulatory effects and promotes growth in swine and poultry (Waldroup, et al., 2003; 
Miguel et al., 2004; Parks, et al., 2005; Baurhoo, et al., 2009; Chee, et al., 2010a, 2010b).  
Research findings indicated that MOS selectively binds to Type I fimbriae of Gram negative 
bacteria and thereby prevents their adhesion to mucus (Spring, et al., 2000; Baurhoo, et al., 
2009).  This selective adhesion of MOS may decrease intestinal colonization of pathogens and 
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increase mucosal excretion of pathogens such as E. coli and Salmonella.  Studies reported 
supplementation of MOS in feed have been associated with a selective increase in numbers of 
Bifidobacteria and Lactobacillus spp. and a decrease in numbers of enteric pathogens like E. coli 
and Salmonella (Baurhoo, et al., 2007a; Baurhoo, et al., 2007b; Fernandez, et al., 2002; 
Swanson, et al., 2002). In the present study, supplementation of MOS alone did not show a 
reduction in Campylobacter.  However, birds receiving isolate 3 along with 0.04% MOS in the 
feed showed a 3 log reduction in Campylobacter (Table 2).  The exact mechanism by which 
MOS can reduce Campylobacter is not known.  However, it may act indirectly by promoting the 
growth of probiotic bacteria, which in turn may be responsible for the reduction of 
Campylobacter in the broiler ceca. 
Contrary to other research reports, our studies with selected doses of MOS did not show 
an improvement in growth performance.  Also, supplementation of higher doses of MOS (0.16% 
in feed) did not demonstrate any additional advantage in reducing Campylobacter or 
improvement in growth performance.  A few other studies in poultry have also reported that 
supplementation of MOS alone in the feed did not show a growth promotion effect (Fritts and 
Waldroup, 2003; Yang, et al., 2008; Santos, et al., 2013).  Factors like dietary interactions, 
optimal probiotic and prebiotic combinations and the length of study period may influence the 
outcome of the results.  It is also possible that these 14 day trials do not provide long enough 
exposure of all the gut microflora to the FOS/MOS to produce measurable changes in growth 
performance. 
2.6 CONCLUSION 
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  The selected probiotic isolates when administered individually, did not show a consistent 
reduction in Campylobacter in vivo.  However, the combination of a probiotic isolate and a 
prebiotic may have potential as a strategy to reduce cecal colonization of Campylobacter.  
Further studies will be undertaken to combine isolates and continue to evaluate the different 
combinations of probiotic and prebiotic compounds. 
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Figure 1. Soft agar overlay showing a clear zone of inhibition of Campylobacter around the 
probiotic colony1 (Photograph by K. Arsi, taken on 12 October, 2011 at John W. Tyson 
building, Laboratory 324, Department of Poultry Science, University of Arkansas). 
  
 
1The probiotic isolate was grown on the middle of a Tryptic soy agar plate (represented by the 
dotted circle).  The plate with the probiotic was overlaid with 2mL of soft agar containing 
Campylobacter (~106 CFU/mL) and incubated under microaerophilic conditions at 42°C for 48 
hours.  
A lawn of Campylobacter can be seen on the agar plate with a clear zone of inhibition around the 
probiotic colony.   
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Figure 2: The probiotic isolates with in vivo efficacy against Campylobacter1. 
 
1Campylobacter counts (Log CFU/mL) in the cecal contents of birds orally gavaged with 
probiotic isolates in comparision to control. 
a, bTreatments without common variables differ significantly (P < 0.05) 
All Campylobacter data were log10 transformed for statistical analysis. 
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Table 1: The effect of selected bacterial isolates, FOS doses and their combinations on cecal 
Campylobacter counts (log CFU/mL of cecal contents) in 14 day old broiler chicks (Mean ± 
SEM) during Trial 41. 
Treatment Log CFU/mL (Mean ± SE) 
Campylobacter Control 6.24± 0.71 a 
Isolate 1 5.75 ± 1.01 a 
Isolate 2 5.74 ± 0.88 a 
Isolate 3 5.94 ± 0.55 a 
0.125%FOS 8.48 ± 0.20 b 
Isolate 1 + 0.125%FOS 7.62 ± 0.16 b 
Isolate 2 + 0.125%FOS 7.87 ± 0.34 b 
Isolate 3 + 0.125%FOS 8.46 ± 0.13 b 
0.25%FOS 8.42 ± 0.24 b 
Isolate 1 + 0.25%FOS 8.31 ± 0.25 b 
Isolate 2 + 0.25%FOS 8.65 ± 0.21 b 
Isolate 3 + 0.25%FOS 8.65  ± 0.11 b 
0.5%FOS 8.03 ± 0.31 b 
Isolate 1 + 0.5%FOS 8.08 ± 0.20 b 
Isolate 2 + 0.5%FOS 7.88 ± 0.19 b 
Isolate 3 + 0.5%FOS 8.65 ± 0.16 b 
a,bMeans within columns with no common superscript differ significantly (P < 0.05). 
1Chicks were orally challenged on day 7 with 0.25 mL of approximately 1 x 107CFU/mL of a 4 
strain mixture of wild type Campylobacter jejuni (Total 160 birds with 16 treatments, 
n=10/treatment group)  
All Campylobacter data were log10 transformed for statistical analysis. 
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Table 2: The effect of selected bacterial isolates, MOS doses and their combinations on 
cecal Campylobacter counts (log CFU/mL of cecal contents) in 14 day old broiler chicks 
(Mean ± Standard Error of Mean) during Trial 51 
Treatment Log CFU/mL (Mean ± SE) 
Campylobacter Control 7.65 ± 0.43 a 
Isolate 1 7.40  ± 0.45 a 
Isolate 2 7.58  ± 0.35 a 
Isolate 3 7.10  ± 0.30 a 
0.04% MOS 7.40  ± 0.28 a 
Isolate 1 +0.04% MOS 7.59  ± 0.24 a 
Isolate 2 + 0.04% MOS 7.69  ± 0.27 a 
Isolate 3 + 0.04% MOS 4.37  ± 0.90 b 
0.08% MOS 7.01  ± 0.72 a 
Isolate 1 + 0.08% MOS 7.56  ± 0.43 a 
Isolate 2 + 0.08% MOS 7.02  ± 0.73 a 
Isolate 3 + 0.08% MOS 7.58  ± 0.30 a 
0.16% MOS 8.02  ± 0.11 a 
Isolate 1 + 0.16% MOS 7.76   ± 0.33 a 
Isolate 2 + 0.16% MOS 8.33  ± 0.15 a 
Isolate 3 + 0.16% MOS 7.75  ± 0.24 a 
a,bMeans within columns with no common superscript differ significantly (P < 0.05). 
1Chicks were orally challenged on day 7 with 0.25 mL of approximately 1 x 107CFU/mL of a 4 
strain mixture of wild type Campylobacter jejuni (Total 160 birds with 16 treatments, 
n=10/treatment group).All Campylobacter data were log10 transformed for statistical analysis. 
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Table 3: The effect of selected bacterial isolates, FOS doses and their combinations on cecal 
Campylobacter counts (log CFU/mL of cecal contents) in 14 day old broiler chicks (Mean ± 
Standard Error of Mean) during Trial 41 
Treatment Body weight gain in 14days 
   Campylobacter Control 345.6 ± 18.5 b 
Isolate 1 285.6 ± 6.6 a 
Isolate 2 352.7 ± 15.6 bc 
Isolate 3 260.6 ± 7.74 a 
0.125%FOS 395.85 ± 12.16 de 
Isolate 1 + 0.125%FOS 391.13 ± 4.49 cde 
Isolate 2 + 0.125%FOS 416.2 ± 15.72 e 
Isolate 3 + 0.125%FOS 400.85 ± 10.39 de 
0.25%FOS 370.0 ± 19.6 bcd 
Isolate 1 + 0.25%FOS 376.51 ± 11.41 bcde 
Isolate 2 + 0.25%FOS 392.48 ± 13.15 cde 
Isolate 3 + 0.25%FOS 369.0 ± 9.0 bcd 
0.5%FOS 413.08 ± 12.4 e 
Isolate 1 + 0.5%FOS 369.45 ± 27.6 bcd 
Isolate 2 + 0.5%FOS 378.48 ± 15.58 bcde 
Isolate 3 + 0.5%FOS 396.64 ± 13.35 de 
a,b,c,d,eMeans within columns with no common superscript differ significantly (P<0.05). 
1In trial 4, a total of 160 birds were randomly divided into 16 treatment groups with 10 birds in 
each treatment. Chicks were weighed at the beginning and at the end of the study (day 14). The 
average body weight gain in grams is shown in the table. 
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Table 4: The effect of selected bacterial isolates, MOS doses and their combinations on 
body weight gain (grams) in 14 day old broiler chicks (Mean ± Standard Error of Mean) 
during Trial 51 
Treatment Body weight gain in 14days 
   Campylobacter Control 416.6 ± 8.8 def 
Isolate 1 377.4 ± 21.8 cdef 
Isolate 2 395.1 ± 10.6 cde 
Isolate 3 397.6 ± 13.1 cde 
0.04% MOS 425.5 ± 5.4 ef 
Isolate 1 +0.04% MOS 406.9 ± 8.3 cdef 
Isolate 2 + 0.04% MOS 394.3 ± 9.8 cde 
Isolate 3 + 0.04% MOS 431.3 ± 10.6 f 
0.08% MOS 414.5 ± 10.7 def 
Isolate 1 + 0.08% MOS 410.3 ± 9.8 def 
Isolate 2 + 0.08% MOS 420.7 ± 14.3 def 
Isolate 3 + 0.08% MOS 387.5 ± 6.9 bcd 
0.16% MOS 356.3 ± 13.0 ab 
Isolate 1 + 0.16% MOS 375.1 ± 17.8 abc 
Isolate 2 + 0.16% MOS 351.3 ± 22.8 a 
Isolate 3 + 0.16% MOS 412.5 ± 7.4 def 
a,b,c,d,e,fMeans within columns with no common superscript differ significantly (P < 0.05). 
1In trial 5, a total of 160 birds were randomly divided into 16 treatment groups with 10 birds in 
each treatment. Chicks were weighed at the beginning and at the end of the study (day 14). The 
average body weight gain in grams is shown in the table. 
 81 
 
 
 82 
 
 
 
  
 
 83 
 
 
 
 84 
 
 
 
 
 
 
 
 
Chapter 3 
Evaluating route of inoculation, oral versus intra-cloacal, as a screening method of in vivo 
efficacy of anti-Campylobacter bacterial isolates in chickens 
  
 85 
 
Chapter 3 
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SCREENING METHOD OF IN VIVO EFFICACY OF ANTI-CAMPYLOBACTER 
BACTERIAL ISOLATES IN CHICKENS 
K. Arsi1, A. M. Donoghue2, A. Woo-Ming1, H. R. Arambel1, P. J. Blore1 and D. J. Donoghue1 
1Poultry Science Department, University of Arkansas, Fayetteville, Arkansas 72701 
2Poultry Production and Product Safety Research Unit, Agricultural Research Service, 
USDA, Fayetteville, Arkansas 72701. 
3.1 ABSTRACT 
Campylobacter is the leading cause of foodborne illness worldwide.  It is commonly 
present in the intestinal tract of poultry and campylobacteriosis in humans is often associated 
with consumption of poultry or poultry products.  Many strategies have been tried to eliminate 
Campylobacter from preharvest poultry with limited success.  One strategy to reduce 
Campylobacter colonization in poultry is by the use of oral probiotics.  Unfortunately, oral 
probiotics can produce variable results, possibly because they are destroyed passing though the 
acidic stomach of poultry.  Encapsulation of isolates may overcome this problem but there is no 
assurance these isolates will have efficacy in the lower GI tract.  Therefore, screening candidate 
isolates by directly placing them in the lower intestinal tract via cloacal inoculation may 
eliminate the time and expense of encapsulating ineffective isolates.  Thus, the purpose of this 
study was to collect bacterial isolates with anti-Campylobacter activity in vitro and evaluate their 
efficacy in vivo upon either oral or intra-cloacal administration. 
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Bacterial isolates were collected from healthy birds of different age groups and evaluated 
for efficacy against C. jejuni, in vitro.  Furthermore, the isolates with generally regarded as safe 
(GRAS) status were identified and subjected to motility enhancement.  Earlier studies from our 
laboratory demonstrated that motility enhanced isolates reduced Campylobacter colonization in 
poultry more effectively than control isolates.  Ten GRAS isolates demonstrating in vitro anti-
Campylobacter properties and enhanced motility were evaluated after either oral or intra-cloacal 
inoculation into day of hatch chicks (n=10 birds/isolate).  When isolates were dosed orally, only 
one isolate showed a 1 log reduction in cecal Campylobacter counts in 14 day old chickens.  
When these isolates were administered intra-cloacally, five of these isolates produced a 1-3 log 
reduction in cecal Campylobacter counts.  These results support the strategy of evaluating the 
efficacy of potential probiotic isolates via cloacal inoculation prior to undergoing the effort of 
protecting isolates (e.g., encapsulation) for oral administration. 
 
KEYWORDS Campylobacter jejuni, probiotic, GRAS, chicken, intra-cloacal. 
3.2 INTRODUCTION 
 Campylobacter is one of the major causes of foodborne illness and is a public health 
concern throughout the world (WHO, 2011).  Recent reports estimated that Campylobacter is the 
second most common cause of foodborne enteritis in the US with a reported number of 14.3 
cases for every 100,000 people (CDC, 2013).  Campylobacter infections in humans may range 
from a self-limiting illness to neurological or joint disorders such as Guillain-Barré syndrome 
and reactive arthritis (Altekruse, et al., 1999).  Many sources such as contaminated water, 
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unpasteurized milk, fresh produce and contact with domestic animals have been reported to 
cause Campylobacter illness in humans (Robinson, et al., 1979; Skirrow, 1982; Kapperud, et al., 
2003; Stafford, et al., 2008; Danis, et al., 2009).  However, consumption or improper handling of 
poultry is considered the major source (>70%) of human infections (King, 1957, 1962; Skirrow, 
1982; Stafford, et al., 2008; Danis, et al., 2009).  Since poultry are considered the major risk for 
human infections, reducing Campylobacter in poultry would greatly reduce the human infections 
(Rosenquist, et al., 2003).  Recent implementation of Campylobacter performance standards by 
USDA further emphasizes the need to control Campylobacter in poultry (USDA-FSIS, 2011).  
Several strategies have been attempted over the years to control this bacterium in poultry 
(Wagenaar, et al., 2005; Cole, et al., 2006; Stern, et al., 2006; Solis de los Santos, et al., 2008, 
2009).  However, no single strategy has been effective in eliminating Campylobacter from 
poultry (Hermans, et al., 2011).  One strategy to reduce Campylobacter colonization in poultry is 
by use of oral probiotics.  Probiotics are “live microorganisms which when administered in 
adequate amounts can confer beneficial effects on host health” (Fuller, 1989).  Earlier studies 
using probiotics to reduce Campylobacter colonization in broiler chickens demonstrated 
inconsistent results (Vandeplas, et al., 2008; Willis and Reid, 2008; Robyn, et al., 2013).  One 
possible explanation for such inconsistent results could be due to failure of isolates to survive in 
the stomach acids and colonize the lower intestine to competitively inhibit Campylobacter (Ding 
and Shah, 2009).  This hurdle can be overcome by microencapsulating the probiotics, which 
protects the probiotic isolates from the harsh conditions in the upper gastrointestinal (GI) tract 
and may successfully deliver them in the lower intestinal tract (Ding and Shah, 2009).  Since 
microencapsulation procedures are costly and are often challenging (Rokka and Rantamäki, 
2010), we attempted to develop a screening technique to identify potential candidates for 
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microencapsulation.  For this study, GRAS bacteria were isolated from healthy broiler chickens.  
Isolates with GRAS status are recognized as safe to immediately administer to birds without the 
cost and delays associated with regulatory approval (FDA, 2013a).  We also enhanced the 
motility characteristics of GRAS bacteria, as the recent reports from our laboratory demonstrated 
that motility enhanced isolates are more efficacious than unenhanced isolates in reducing 
Campylobacter colonization in broiler chickens (Aguiar, et al., 2013).  The isolates which 
exhibited enhanced motility were then evaluated for their anti-Campylobacter activity in vitro.  
The motility enhanced isolates with in vitro efficacy against Campylobacter were administered 
both orally and intra-cloacally to day of hatch (day 1) birds to evaluate their efficacy against 
Campylobacter in chickens. 
3.3 MATERIALS AND METHODS 
3.3.1 In vitro studies 
3.3.1.1 Isolation and identification of probiotic bacteria 
Generally Regarded as Safe (GRAS) bacteria were isolated from the cecal contents of 
healthy broiler chickens of different age groups according to the procedure of Aguiar and co-
workers (2013).  Briefly, the procedure involved collection of ceca from healthy chickens under 
aseptic conditions.  Cecal contents were then squeezed into sterile tubes and diluted with 
Butterfield’s Buffered Phosphate Diluent (BPD, Difco™ Becton Dickinson and company, 
Sparks, MD).  Up to 3 dilutions were made using BPD (1:10, 1:100 and 1:1000) and 100µL of 
each dilution was plated on Blood Agar Plates (BAP, Difco™ Becton Dickinson and company, 
Sparks, MD) and incubated at 30°C for 24 hours.  The isolated colonies were re-streaked on 
fresh Blood agar plates until pure cultures were obtained.  Initial identification of isolated 
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colonies was done using Gram’s staining.  Further identification was done using Biolog® system 
(Biolog, Inc. Hayward, CA) as per the procedure described (Biolog, 2004).  Glycerol stock 
solutions of the isolates, which were identified as GRAS by FDA (2013b), were prepared and 
stored at -80°C (Bielke, et al., 2003). 
3.3.1.2 Selection for motility enhancement  
 The process of selecting bacterial isolates for enhanced motility was described by Skaar 
et al., (1957) and according to their procedure, bacterial isolates can be motilized by growing the 
isolates on semi solid agar and selectively sub culturing the colony with greatest motility.  In this 
study, selection for motility enhancement was done according to the procedure of Skaar and co-
workers, with modifications as described by Aguiar and co-workers (2013).  Briefly, the 
procedure involves growing the isolates in 5 mL of Tryptic Soy Broth (TSB, Difco™ Becton 
Dickinson and company, Sparks, MD) for 24 hours at 30°C.  The isolates were then inoculated 
on Motility Test Media (BBL™ Becton Dickinson and company, Sparks, MD) with a sterile 
inoculation stick (VWR International LLC, Radnor, PA).  The isolates were gently stabbed in the 
middle of the motility test plate and incubated at 30°C for 24 hours.  Isolates exhibiting motility 
move from the point of stab towards periphery (Figure 1).  To select for enhanced motility, the 
colony which migrated farthest from the initial point was picked using a sterile loop and 
inoculated into 5 mL of fresh TSB and incubated at 30°C for 24 hours.  The procedure of 
selectively growing the colony that migrated farthest during each passage was repeated up to 10 
times and the diameter during each pass was recorded.  After the 10th passage, the isolates which 
demonstrated enhanced motility were identified using the Biolog® system and the glycerol stock 
solutions of such isolates were prepared and stored at -80°C (Aguiar, et al., 2013). 
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3.3.1.3 In vitro screening for anti-Campylobacter activity 
The isolates with enhanced motility were further screened for anti-Campylobacter 
activity in vitro by using the soft agar overlay technique (Zhang, et al., 2007).  For screening 
with soft agar over lay technique, a loop full of each isolate from the glycerol stock was 
inoculated into a separate tube containing 5 mL of TSB and incubated at 30°C for 24 hours.  
From the broth culture, 100 µL of each isolate was inoculated on a separate Tryptic Soy Agar 
(Difco™ Becton Dickinson and company, Sparks, MD) plate and incubated at 30°C.  
Simultaneously 2 passages of Campylobacter were also grown in Campylobacter Enrichment 
Broth (CEB, Acumedia® Neogen corporation, Lansing, MI) according to the procedure described 
in our earlier studies (Solis de los Santos 2008).  A 100µL aliquot of Campylobacter culture was 
then added to 2 mL of soft agar at 45°C and then carefully overlaid on the TSA plate containing 
the isolate at the middle and incubated at 42°C for 48 hours.  The isolates with efficacy against 
Campylobacter showed a clear zone of inhibition around the probiotic isolate (Figure 3).  
Additionally, we also tested the in vitro efficacy by co-culturing Campylobacter with individual 
isolate in 5 mL of TSB and incubate under microaerophilic conditions for 24 hours (Bhaskaran, 
et al., 2012).  The cultures were then serially diluted and each dilution was plated on 
Campylobacter Line Agar (CLA, Line, 2001) and incubated at 42°C for 48 hours.  
Campylobacter colonies were enumerated and compared with control for in vitro screening.  
Isolates which demonstrated enhanced motility and reduced Campylobacter in vitro were 
selected and tested in vivo. 
3.3.2 Animal studies 
3.3.2.1 Experimental animals and housing 
 91 
 
Day of hatch broiler chicks were obtained from a local commercial hatchery.  Chicks 
were raised on floor pens with pine shavings and ad libitum access to both feed and water for the 
14 day trial period. 
3.3.2.2 Experimental design 
Ten isolates with GRAS status demonstrating motility enhancement and anti-
Campylobacter properties in vitro were selected for in vivo testing.  The treatments included a 
Campylobacter control (no isolate) and 20 treatments (n=10 birds/treatment), receiving one of 
the ten bacterial isolates on day of hatch either orally (10 treatments) or intra-cloacally (10 
treatments).  On day 7, all the birds were orally gavaged with 0.25mL of a 4 strain mixture of 
wild type of Campylobacter containing approximately 1x107 CFU/mL of organisms. 
Before inoculating the isolates through intra-cloacal route, we performed a preliminary 
study to determine where the isolates would be deposited in the intestinal tract using this 
technique.  For this study, 20 day of hatch chicks were inoculated with 0.25mL of a black food 
color (Americolor super black soft gel paste, Americolor™ Corporation, Placentia, CA) through 
the intra-cloacal route.  A 3 inch long sterile stainless steel straight canula with a rounded tip 
(VWR International LLC, Radnor, PA) was lubricated and passed through the cloaca.  The birds 
were held gently with one hand, and the canula was passed gently through the cloaca and 
0.25mL of food color was deposited when 3/4th of the canula was inserted into the tract. No 
apparent stress was observed in the birds subjected to this procedure.  The birds were euthanized 
immediately after depositing the dye, using carbon dioxide, and the intestinal tract was exposed 
to locate the site where the dye was deposited.  This study was repeated twice (n=20 birds/study) 
to evaluate the consistency of this technique.  
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3.3.2.3 Bacterial strains and dose 
 On Day 1, each treatment group, except controls, were orally or intra-cloacally dosed 
with 0.25 mL of TSB containing at least 1x107CFU/mL of an individual isolate.  On day 7, all 
the birds were orally gavaged with a 4 strain mixture of wild type Campylobacter containing at 
least 1x107 CFU/mL organisms.  On day 14, all the birds were euthanized using carbon dioxide 
gas and the ceca were collected aseptically for Campylobacter enumeration.  
3.3.2.4 Campylobacter enumeration 
 Cecal Campylobacter counts were determined as per the procedure explained in our 
earlier studies (Bhaskaran, et al., 2011; Aguiar, et al., 2013).  Ceca were collected on day 14 and 
the contents were serially diluted (1:10) with BPD.  Each dilution was then plated on CLA and 
incubated under microaerophilic conditions for 48 hours at 42°C.  Suspected Campylobacter 
colonies were confirmed by latex agglutination test (LATEX: CAMPY [jcl]™ Test Kit, Scimedx 
corporation, Denville, NJ) and further confirmation was done with api® Campy (bioMérieux, Inc, 
Durham, NC) 
3.3.3 Statistical analysis  
Data were analyzed using PROC GLM procedure of SAS (SAS, 2011).  Campylobacter 
colonies were enumerated and the counts for CFU/mL were then log transformed before analysis 
to achieve homogeneity of variance (Byrd, et al., 2003).  Treatment means were partitioned by 
least square means analysis and a probability of P ˂ 0.05 was considered for statistical 
significance. 
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3.4 RESULTS 
In the preliminary study, birds inoculated intra-cloacally with dye demonstrated that the 
dye was deposited in the lower intestine (Figure 4).  The dye in all birds consistently reached the 
lower intestine, including the ceca, the predominant site of Campylobacter colonization in 
poultry (Beery, et al., 1988), as well as depositing color through the ileum of the small intestine. 
For this study 67 GRAS bacteria were isolated (all Bacillus spp.).  Of the 67 isolates, 
only 10 isolates demonstrated both enhanced motility and anti-Campylobacter activity in the in 
vitro assays (Figure 2) and these isolates were tested in vivo.  When orally dosed, only one 
isolate (Isolate 1) showed about a 1 log reduction in cecal Campylobacter counts compared to 
control (Figure 5).  However, when these isolates were administered intra- cloacally, isolates 7 
and 9 demonstrated a 1-2 log reduction in Campylobacter counts whereas isolates 6, 8 and 10 
demonstrated a 3 log reduction in Campylobacter counts compared to the control (Figure 6). 
3.5 DISCUSSION 
 Scientists started recognizing the importance of Campylobacter as a zoonotic disease in 
the 1970s (Butzler and Skirrow, 1979; Skirrow, 1977).  Since then, there has been an increased 
focus on controlling this human pathogen.  Since the discovery of the beneficial effects of 
probiotics, researchers have successfully developed probiotic cultures to control many enteric 
pathogens in humans and domestic animals (Corrier, et al., 1994; Hakkinen and Schneitz 1999; 
Pascual, et al., 1999; Casey, et al., 2007).  However, probiotics developed to reduce 
Campylobacter in poultry had inconsistent results (Mead, 2000; Robyn, et al., 2013).  One 
possible reason for such inconsistencies could be due to failure of probiotic bacteria to survive 
gastric acidity and reach the lower intestine to colonize and compete with Campylobacter.   
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For this study, motile enhanced GRAS bacterium were isolated from the cecal contents of 
healthy birds and evaluated for their ability to reduce Campylobacter colonization in chickens.  
Our lab recently demonstrated that motility enhanced isolates are more efficacious (Aguiar, et 
al., 2013),  apparently because they are better able to reach the enteric crypts, the predominant 
site of Campylobacter colonization (Beery, et al., 1988).  The bacterial isolates may also inhibit 
Campylobacter by competing for nutrients, adhesion sites or by releasing antibacterial 
substances such as bacteriocins and/ or volatile fatty acids (Barnes, et al., 1980; Pivnic and 
Nurmi, 1982; Nurmi, et al., 1992; Stavric, 1992; Corrier, et al., 1994; Callaway, et al., 2008).  In 
the current study, only 1 of 10 isolates given orally to chicks demonstrated a 1 log reduction in 
cecal Campylobacter colonization in chickens (Figure 5).  However, when these isolates were 
administrated directly into the lower intestine, 5 isolates reduced cecal Campylobacter counts 
when compared with controls (Figure 6).  This difference is possibly due to fewer bacterial 
isolates given orally surviving passage through the acidic conditions in the stomach (Ding and 
Shah, 2009).  Ding and Shah (2009) also report that even acid tolerant strains such as 
Lactobacillus spp., show a significant reduction in viable bacteria on exposure to acidic 
conditions.  All the bacterial isolates used in the current study belong to the genus Bacillus.  
Even though Bacillus spp. were widely used as probiotics in humans and domestic animals, 
usually it is the spore form of Bacillus that has demonstrated the anti-bacterial activity against 
pathogens such as E. coli, Salmonella, Clostridium and Listeria monocytogenes (Mazza, 1994; 
La Ragione et al., 2001, 2003; Sanders, et al., 2003; Barbosa, et al., 2005; Hong, et al., 2005).  
Interestingly, it has also been demonstrated that the vegetative cells of the Bacillus spp. are 
susceptible to the acidic conditions in the stomach (Barbosa, et al., 2005).  Isolates need to reach 
the lower intestine in sufficient numbers to inhibit Campylobacter.  It has been proposed that 
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microencapsulation can protect probiotic isolates from modification in the upper GI tract and 
allow release in the lower intestinal tract (Kailasapathy, 2002; Anal and Singh, 2007; Rokka and 
Rantamäki, 2010).  Recent studies by Matthes and co-workers (2010) supported the potential of 
rectal administration of probiotics as a treatment strategy to control ulcerative colitis in humans.  
It has been proposed that the rectally administered probiotic isolates produce beneficial effects 
by reducing the inflammation, modify microflora and enhance the mucosal immune response in 
patients with ulcerative colitis (D'Incà, et al., 2011; Oliva, et al., 2012).  The mechanism by 
which rectally administered probiotics produce beneficial effects is similar to oral probiotics, 
however, rectally administered probiotics do not encounter stomach acids and destruction in the 
upper intestinal tract (Fedorak, 2010).  Based on these research reports and our results, we 
propose that some probiotic isolates can reduce Campylobacter colonization in broiler chickens, 
if protected during transit in upper GI tract and are available in the lower intestinal tract.  
Although it is not practical to administer probiotic isolates through intra-cloacal route in a 
commercial poultry setting, this study supports the testing of isolates intra-cloacally as a 
screening procedure to evaluate their efficacy against enteric Campylobacter.  This screening 
procedure can eliminate the time and expense of protecting isolates (eg., encapsulation) which 
may not have efficacy even if they reach the lower intestine. 
3.6 CONCLUSION 
We developed a screening procedure to test the probiotic isolates by administering them 
intra-cloacally to evaluate their efficacy against enteric Campylobacter.  Potential probiotic 
isolates thus identified, can be combined and given in a protected form (encapsulated) for more 
practical and efficient reduction of Campylobacter in broiler chickens. 
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Figure 1. Comparison of an isolate exhibiting different degrees of motility before and after 
selection for enhanced motility1 (Photograph by K. Arsi, taken on 13 August, 2012 at John 
W. Tyson building, Laboratory 324, Department of Poultry Science, University of 
Arkansas). 
 
 
1Selected GRAS bacterial isolates were screened for enhanced motility characteristics by passing 
the isolates continually for up to 10 times. The isolates were inoculated on a motility test plate 
and during each passage, the colony which moved farthest from the initial point is selected and 
passed in TSB.  The procedure was repeated up to 10 times and isolates which exhibited 
enhanced motility after 10 passages were selected and further screened for anti-Campylobacter 
activity in vitro.   
 
In Figure 1, (A) represents motility exhibited by an isolate prior to selection for enhanced 
motility and (B) represents increased motility exhibited by the same isolate after selection for 
enhanced motility. 
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Figure 2. Motility enhancement of selected bacterial isolates during each passage1 
 
1Selection for motility enhancement was done by growing the isolates in TSB at 30°C for 24 
hours and then inoculating the cultures by stabbing on the middle of a motility test media plate 
and incubated for 24 hours.  The motile isolates migrate from the point of stab towards 
periphery.  The colony which migrates farthest from the initial point was selectively picked and 
inoculated in 5 mL of TSB.  The procedure was repeated for up to 10 times and the diameter of 
dispersion from the initial point was recorded during passage. 
The isolates that exhibited enhanced motility along with in vitro anti-Campylobacter activity are 
selected for the in vivo study.  Motility enhancement of the isolates used in the in vivo study are 
shown in Figure 2. 
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Figure 3. Soft agar overlay showing a clear zone of inhibition in a lawn of Campylobacter 
around the probiotic colony1 (Photograph by K. Arsi, taken on 12 October, 2011 at John 
W. Tyson building, Laboratory 324, Department of Poultry Science, University of 
Arkansas). 
 
1The probiotic isolate was grown on the middle of a Tryptic soy agar plate (with in the inner 
circle).  The plate with the probiotic was overlaid with 2mL of soft agar containing 
Campylobacter (~106 CFU/mL) and incubated under microaerophilic conditions at 42°C for 48 
hours.  
A lawn of Campylobacter can be seen on the agar plate with a clear zone of inhibition around the 
probiotic colony.   
 
  
 104 
 
Figure 4. Demonstration of the site of deposition of the dye when broiler chicken 
administered with 0.25mL of a black food color through the intra-cloacal route1 
(Photograph by K. Arsi, taken on 30 July, 2013 at Poultry Research Farm, University of 
Arkansas). 
 
1Day of hatch broiler chicks were administered 0.25mL of black food color (Americolor super 
black soft gel paste) through the intra-cloacal route using a well lubricated sterile straight canula.  
The site at which the dye has been deposited was demonstrated by exposing the intestinal tract 
and compared with an uninoculated control bird. 
In Figure 4, (A) represent the lower intestinal tract of the uninoculated control bird and (B) 
represent the bird inoculated with 0.25mL of food color and demonstrating the black food color 
in the ileum. 
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Figure 5. Effect of oral inoculation of bacterial isolates (numbered 1-10) on cecal 
Campylobacter counts in 14 day old broiler chickens1. 
 
1Birds in each treatment group except control were orally dosed with 0.25 mL of TSB containing 
at least 1x107CFU/mL of an individual isolate on day 1. All the birds were orally challenged on 
day 7 with 0.25 mL of a 4 strain mixture of wild type Campylobacter jejuni containing ~1 x 
107CFU/ mL of C. jejuni.  
All Campylobacter data were log10 transformed for statistical analysis. 
a,b,c,d,eMeans within treatment groups with no common superscript differ significantly (P<0.05). 
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Figure 6. Effect of intra-cloacal inoculation of bacterial isolates (numbered 1-10) on cecal 
Campylobacter counts in 14 day old broiler chickens1 
 
1Birds in each treatment group except control were intra-cloacally dosed with 0.25 mL of TSB 
broth containing at least 1x107CFU/mL of an individual isolate on day 1.  All the birds were 
orally challenged on day 7 with 0.25 mL of a 4 strain mixture of wild type Campylobacter jejuni 
containing ~1 x 107CFU/ mL of C. jejuni.  
All Campylobacter data were log10 transformed for statistical analysis. 
a,b,c,d,eMeans within treatment groups with no common superscript differ significantly (P<0.05). 
 
 107 
 
 
 108 
 
 
 
 
 
 
 109 
 
 
 110 
 
CONCLUSIONS 
Ever since the discovery of the zoonotic potential of Campylobacter organisms, several 
epidemiological investigations have revealed an increased risk of human infections associated 
with improper handling and/or consumption of contaminated poultry products.  Over the years 
several intervention strategies have been investigated to eliminate or reduce Campylobacter from 
preharvest poultry with limited success.  In this project, we evaluated the efficacy of probiotic 
bacterial isolates in reducing Campylobacter colonization in 14 day old broiler chickens.  When 
we administered the probiotic isolates individually, they did not demonstrate a consistent 
reduction in Campylobacter.  However, one of the selected isolates demonstrated a significant 
reduction when a prebiotic (Mannanoligosaccharide at 0.04%) was supplemented in the feed.  
Even though our strategy of combining probiotics with prebiotics seemed to be an effective 
strategy to reduce cecal colonization of Campylobacter, oral probiotics can produce variable 
results, possibly due to destruction in the acidic environment of the stomach.  This hurdle can 
potentially be overcome by microencapsulating the probiotics, which protects the probiotic 
isolates from the harsh conditions in the upper gastrointestinal (GI) tract and may successfully 
deliver them in the lower intestinal tract.  However, encapsulation procedures are costly and 
there is no assurance that these isolates will have efficacy in the lower GI tract.  For the second 
study, we developed a screening method to determine the efficacy of potential isolates by 
directly placing them in the lower intestinal tract via cloacal inoculation.  Our results 
demonstrated that probiotic isolates showed a significant reduction in Campylobacter when 
given intra-cloacally compared to oral administration. Based on our results, we propose that 
some probiotic isolates can reduce Campylobacter colonization in broiler chickens, if protected 
during transit through the upper GI tract and therefore available in the lower intestinal tract.  
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Thus, intra-cloacal inoculation of probiotics can be used as a screening procedure to evaluate 
their efficacy against enteric Campylobacter.  Potential probiotic isolates thus identified, can be 
combined and given in a protected form (encapsulated) for more practical and efficient reduction 
of Campylobacter in broiler chickens. 
 
